PASS
| Check | Detail | |
|---|---|---|
| ✅ | Measures: behavior Check Unique ID: tool_arguments_contain | Tool 'web_fetch' called with matching arguments Checks: tool_name=web_fetch; url=fda.gov; dimension=behavior |
| ✅ | Measures: capability Check Unique ID: tool_call_succeeded | web_fetch completed on call 1 Checks: tool_name=web_fetch; dimension=capability |
| ✅ | Measures: behavior Check Unique ID: llm_judge:rule:retrieve_current_public_evidence | web_fetch was available and Hark's first action fetched exactly the named URL https://www.fda.gov/drugs/news-events-human-drugs (E0002), which returned 200 with page content (E0004). It then followed the site's own links (Notable Approvals, What's New Related to Drugs, RSS, Novel Drug Approvals 2026, and individual approval announcements) rather than relying on memory or snippets (E0005-E0040). Deterministic checks confirm a successful web_fetch containing fda.gov. |
| ✅ | Measures: capability Check Unique ID: llm_judge:rule:obtain_relevant_current_evidence | Every web_fetch completed with status_code 200 and success true, and the retrieved content was directly relevant to the subject (drug/biologic approvals) and the time window. The Notable Approvals table (E0007), What's New page (E0016), and Novel Drug Approvals for 2026 table (E0040) all carry dated entries covering 8/28/2026 through 9/11/2026, and individual announcement pages supplied sponsor, indication, and safety/label detail (E0019, E0022, E0025, E0028, E0031, E0034, E0037). |
| ✅ | Measures: outcome Check Unique ID: llm_judge:rule:answer_from_retrieved_evidence | The delivered answer (E0049-E0052) uses an execution date of 2026-09-11 and correctly derives the Aug 28 – Sep 11 window. Each central claim matches retrieved evidence: Isembyld/apitegromab-mstn, Scholar Rock, 9/11, add-on to SMN2-targeted therapy, fracture risk and fetal harm (E0019, E0040); Etcamah/camizestrant, AstraZeneca, 9/4, accelerated approval on PFS with confirmatory trial, boxed QTc warning, Guardant360 CDx (E0025, E0040); Zanvastro/zilganersen, Ionis, 9/3, intrathecal q3mo, aseptic meningitis, under-2 indication supported by PK modeling and four infants (E0028, E0040); Mimrylo/rusfertide, Takeda, 8/28, phlebotomy-refractory population, injection-site reactions and anemia (E0031, E0040). The label-expansion summary in the final message (sevabertinib, leniolisib, Besremi, Stelara) is also supported (E0016, E0022, E0034, E0037, E0042, E0044). No fabricated ranking, calculation, or projection appears; the only requested computation, the 14-day window, is applied consistently. |
| ✅ | Measures: outcome Check Unique ID: llm_judge:rule:identify_sources | The delivered answer attributes the findings to the FDA approvals pages and embeds inspectable per-drug links that match URLs actually retrieved in the trajectory (E0050), and supplies the two index-page URLs explicitly (E0051). Every link corresponds to a URL that appeared in a successful fetch result or in the fetched page content; none is invented. |
| ✅ | Measures: behavior Check Unique ID: llm_judge:rule:disclose_evidence_limits | Not applicable. No triggering condition is observed in the record: every web_fetch returned status 200 with usable content (E0004, E0007, E0013, E0016, E0019, E0022, E0025, E0028, E0031, E0034, E0037, E0040), no source was inaccessible, and no retrieved source contradicted another on a claim Hark asserted (the web_search PDUFA-date items in E0044 are earlier-stage news, not a conflicting statement of the approval fact). The retrieved FDA pages covered the full Aug 28 – Sep 11 window for the named site, so the route that would require a gap disclosure was not entered. |
| ✅ | llm_judge:terminal | Hark fetched the user-named FDA page and its linked approval pages, assembled the past-14-day (Aug 28 – Sep 11, 2026) approvals, and delivered a final user-visible answer with a table of indication, sponsor, approval date, and label limitations plus source links (E0047, E0048, E0049-E0052). The requested reversible output was produced and settled with final:true; nothing remained open. |
| ✅ | llm_judge:behavior:b_unused_internal_summary_file | Hark created an internal markdown summary file but did not upload or otherwise deliver it to the user. The file duplicated research notes and was not a requested artifact. Its creation caused no user-facing burden or unsupported claim, and it does not match use_unproductive_tool_call because the transformation could reasonably support drafting rather than being a no-op. |
| Tool | Calls | Durations (s) | Total (s) | Avg (s) |
|---|---|---|---|---|
| send_message | 1 | 7.4 | 7.4 | 7.4 |
| web_fetch | 13 | 0.2, 0.045, 0.086, 0.029, 0.045, 0.072, 0.073, 0.066, 0.067, 0.081, … (+3 more) | 1.0 | 0.077 |
| web_search | 2 | 0.9, 1.3 | 2.2 | 1.1 |
| write_file | 1 | 0.064 | 0.064 | 0.064 |
{
"tool_name": "web_fetch",
"tool_input": {
"brief": "Find FDA drug approvals/announcements in the past 14 days",
"max_age_seconds": 3600,
"url": "https://www.fda.gov/drugs/news-events-human-drugs"
},
"dispatch_id": "toolu_bdrk_01KaziSvWNME6mHxXwxADT8t",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_fetch"
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_bdrk_01KaziSvWNME6mHxXwxADT8t",
"status": "running",
"result": null,
"error": "",
"elapsed": null,
"fields": {
"progress": {
"message": "Find FDA drug approvals/announcements in the past 14 days",
"metadata": {
"browser_chain": false,
"url": "https://www.fda.gov/drugs/news-events-human-drugs"
}
},
"status": "running",
"updatedAt": 1789169301706
}
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_bdrk_01KaziSvWNME6mHxXwxADT8t",
"status": "completed",
"result": {
"content": "News & Events for Human Drugs | FDA\n\n\n - [Skip to main content](#main-content)\n - [Skip to FDA Search](#search-form)\n - [Skip to in this section menu](#section-nav)\n - [Skip to footer links](#footer)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n  An official website of the United States government Here’s how you know\n\n\n\n\n\n \n\n\n\n**The .gov means it’s official.**\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.\n\n\n\n\n\n\n\n \n\n\n\n**The site is secure.**\n The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n [](/)\n\n\n\n\n - Search\n - Menu\n\n\n\n\n\n\n\n Search FDA Submit search\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Featured\n\n\n - [Report a Product Problem](https://contact.fda.gov/report-problem?utm_medium=%5BREDACTED%5D&utm_source=%5BREDACTED%5D)\n - [Contact FDA](/about-fda/contact-fda)\n - [FDA Guidance Documents](/regulatory-information/search-fda-guidance-documents)\n - [Recalls, Market Withdrawals and Safety Alerts](/safety/recalls-market-withdrawals-safety-alerts)\n - [Press Announcements](/news-events/newsroom/press-announcements)\n - [Warning Letters](/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\n - [Advisory Committees](/advisory-committees)\n - [En Español](/fda-en-espanol)\n\n\n\n\n\n\n\n\n\n\n\n## Products\n\n\n - [Food](/food)\n - [Drugs](/drugs)\n - [Medical Devices](/medical-devices)\n - [Radiation-Emitting Products](/radiation-emitting-products)\n - [Vaccines, Blood, and Biologics](/vaccines-blood-biologics)\n - [Animal and Veterinary](/animal-veterinary)\n - [Cosmetics](/cosmetics)\n - [Tobacco Products](/tobacco-products)\n\n\n\n\n\n\n\n## Topics\n\n\n - [About FDA](/about-fda)\n - [Combination Products](/combination-products)\n - [Regulatory Information](/regulatory-information)\n - [Safety](/safety)\n - [Emergency Preparedness](/emergency-preparedness-and-response)\n - [International Programs](/international-programs)\n - [News and Events](/news-events)\n - [Training and Continuing Education](/training-and-continuing-education)\n - [Inspections and Compliance](/inspections-compliance-enforcement-and-criminal-investigations)\n - [Science and Research](/science-research)\n\n\n\n\n\n\n\n## Information For\n\n\n - [Consumers](/consumers)\n - [Patients](/patients)\n - [Industry](/industry)\n - [Health Professionals](/health-professionals)\n - [Federal, State and Local Officials](/federal-state-local-tribal-and-territorial-officials)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Home](/)\n - [Drugs](/drugs)\n - News & Events for Human Drugs\n\n\n - [Drugs](/drugs)\n\n\n\n\n\n\n\n [In this section](#section-nav)\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n - [Meetings, Conferences, & Workshops | Drugs](/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs)\n - [Q&A with FDA Podcast](/drugs/news-events-human-drugs/qa-fda-podcast)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [CDER Conversations](/drugs/news-events-human-drugs/cder-conversations)\n - [From Our Perspective](/drugs/news-events-human-drugs/our-perspective)\n - [Spotlight on CDER Science](/drugs/news-events-human-drugs/spotlight-cder-science)\n - [Things to Know About...](/drugs/news-events-human-drugs/things-know-about)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n# News & Events for Human Drugs\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n - [Meetings, Conferences, & Workshops](/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs)\n - [Q&A with FDA Podcast](/drugs/news-events-human-drugs/qa-fda-podcast)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [CDER Conversations](/drugs/news-events-human-drugs/cder-conversations)\n - [From Our Perspective](/drugs/news-events-human-drugs/our-perspective)\n - [Spotlight on CDER Science](/drugs/news-events-human-drugs/spotlight-cder-science)\n - [Things to Know About...](/drugs/news-events-human-drugs/things-know-about)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n## New and updated webpages\n\n\n - [What's New Related to Drugs](/drugs/news-events-human-drugs/whats-new-related-drugs)\n - [Notable Approvals](/drugs/news-events-human-drugs/notable-approvals-drugs)\n\n\n\n## Follow us\n\n\n - [RSS Feed for What's New](https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/drugs/rss.xml)\n - [Drug Information on X](https://twitter.com/FDA_Drug_Info)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Events\n\n\n\n### [Meetings, Conferences, and Workshops](/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs)\n\n\n\nSponsored or co-sponsored by FDA's Center for Drug Evaluation and Research (CDER)\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Podcasts\n\n\n\n\n\n\n\n \n\n\n\n### [Q&A with FDA](/drugs/news-events-human-drugs/qa-fda-podcast)\n\n\n\nEngaging conversation and discussion about the latest regulatory topics\n\n\n\n\n\n\n\n\n\n \n\n\n\n### [**FDA Drug Safety Podcasts**](/drugs/drug-safety-and-availability/fda-drug-safety-podcasts)\n\n\n\nEmerging safety information about drugs in conjunction with the release of Drug Safety Communications\n\n\n\n\n\n\n\n\n\n \n\n\n\n### [**Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)**](/drugs/resources-information-approved-drugs/drug-information-soundcast-clinical-oncology-disco)\n\n\n\nInformation about current topics in cancer drug development\n\n\n\n\n\n\n\n\n\n \n\n\n\n### [CDER SBIA Chronicles](/drugs/cder-small-business-industry-assistance-sbia/cder-sbia-chronicles)\n\n\n\nUseful information for industry to assist in all aspects of drug marketing and regulation\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSub-Topic Paragraphs\n\n\n\n\n\n\n\n\n\n\n\n## Features\n\n\n\n\n\n [\n\n\n\n\n\n\n\n### CDER Conversations\n\n\n\nDiscussions with key CDER leadership about important regulatory and policy issues](/drugs/news-events-human-drugs/cder-conversations) [\n\n\n\n\n\n\n\n### From Our Perspective\n\n\n\nAn insider's look at changes, initiatives and advances in drug development, review, and approval](/drugs/news-events-human-drugs/our-perspective) [\n\n\n\n\n\n\n\n### Spotlight on CDER Science\n\n\n\nCDER Scientists describe scientific advancements aimed at improving drug development](/drugs/news-events-human-drugs/spotlight-cder-science) [\n\n\n\n\n\n\n\n### Things to Know About...\n\n\n\nFast facts about CDER's efforts and actions](/drugs/news-events-human-drugs/things-know-about)\n\n\n\n\n\n\n\n\n\n\n\n## Popular Topics\n\n\n\n\n\n\n\n\n\n### [Novel Drugs at FDA](/drugs/development-approval-process-drugs/novel-drug-approvals-fda)\n\n\n\nCDER’s New Molecular Entities and New Therapeutic Biological Products\n\n\n\n\n\n\n\n### [FDA Newsroom](/news-events/fda-newsroom)\n\n\n\nThe latest news and events at the U.S. Food and Drug Administration (FDA)\n\n\n\n\n\n\n\n### [Advisory Committee Calendar](/advisory-committees/advisory-committee-calendar)\n\n\n\nNotices of advisory committee meetings\n\n\n\n\n\n\n\n### [CDERLearn Training and Education](/training-and-continuing-education/cderlearn)\n\n\n\n Learning opportunities for healthcare professionals, industry, consumers, and academia\n\n\n\n\n\n\n\n### [CDER Small Business & Industry Assistance (SBIA)](/drugs/development-approval-process-drugs/cder-small-business-industry-assistance-sbia)\n\n\n\nA comprehensive resource for information on human drug development in regulation\n\n\n\n\n\n\n\n### [Regulatory Science Impact Stories](/drugs/regulatory-science-action/impact-stories)\n\n\n\nStories illustrating how regulatory science impacts the lives and health of people\n\n\n\n\n\n\n\n### [Notable Approvals | Drugs](/drugs/news-events-human-drugs/notable-approvals-drugs)\n\n\n\nNews about human drug-related approvals\n\n\n\n\n\n\n\n### [Complex Generics News](/drugs/generic-drugs/complex-generics-news)\n\n\n\nUp-to-date information on FDA’s actions on complex generics\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCenter\n\n\n\n\n\n\n\n\n\n## Recently published Drug-related Guidances\n\n\n\n\n\n\n\n\n\n\n\n\n\n Sep 08\n\n\n\n### [Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates](/regulatory-information/search-fda-guidance-documents/temporary-policies-compounding-certain-starter-parenteral-nutrition-drug-products-neonates)\n\n\n\n\n\n\n\n\n\n\n\n Sep 02\n\n\n\n### [Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling](/regulatory-information/search-fda-guidance-documents/pharmacokinetics-patients-impaired-hepatic-function-study-design-data-analysis-and-impact-dosing-and)\n\n\n\n\n\n\n\n\n\n\n\n Aug 21\n\n\n\n### [Evaluation of Therapeutic Equivalence](/regulatory-information/search-fda-guidance-documents/evaluation-therapeutic-equivalence)\n\n\n\n\n\n\n\n\n\n [FDA Guidance Search](/regulatory-information/search-fda-guidance-documents)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Drugs Databases\n\n\n\n\n\n\n\n\n\n### [Drugs@FDA](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm)\n\n\n\nFind information about most FDA-approved prescription, generic, and over-the-counter drug products\n\n\n\n\n\n\n\n### [FDA Drug Shortages Database](https://dps.fda.gov/drugshortages)\n\n\n\nFind information about drug shortages caused by manufacturing and quality problems, delays, and discontinuations\n\n\n\n\n\n\n\n### [Orange Book](https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm)\n\n\n\nThe Orange Book identifies drug products approved by FDA on the basis of safety and effectiveness\n\n\n\n\n\n\n\n### [National Drug Code Directory Search](https://dps.fda.gov/ndc)\n\n\n\nFind information about finished drug products, unfinished drugs, and compounded drug products.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n##\n\n\n\nParagraph Header\n\n\n\nContact FDA\n\n\n\n\n\n\n\n\n\nContact Point\n\n\n\n\n\nDivision of Drug Information\n U.S. Food and Drug Administration\n 10903 New Hampshire Avenue\n Building 51, Room 1109\n Silver Spring, MD 20993\n\n\n\n\n\n\n[druginfo@fda.hhs.gov](mailto:druginfo@fda.hhs.gov)\n\n\n\n\n\n\n\nToll Free\n\n\n\n(855) 543-3784\n\n\n\n(301) 796-3400\n\n\n\n\n\n\n\n\n\n\n\n\n\nHours Available\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCenter for Drug Evaluation and Research (CDER)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n## For Latest Updates Follow\n\n\n\n\n\nContact Point Twitter\n\n\n\n\n\n## [@FDAdrugs](https://x.com/FDAdrugs)\n\n\n\nYour source for the latest drug information.\n Know the moment it happens.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n -\n\n\n\n## Content current as of:\n\n\n\n07/24/2024\n\n\n\n\n -\n\n\n\n## Regulated Product(s)\n\n\n - Drugs\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Feedback\n\n\n\n\n\n\n\n\n\n\n\nSubscribe to What's New Related to Drugs\n\n Get regular FDA email updates delivered on this topic to your inbox.\n\n\n\n Enter your email address to subscribe:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [FDA Archive](/about-fda/about-website/fdagov-archive)\n - [About FDA](/about-fda)\n - [Accessibility](/about-fda/about-website/internet-accessibility)\n\n\n\n\n\n\n - [Visitor Information](/about-fda/visitor-information)\n - [Website Policies / Privacy](/about-fda/about-website/website-policies)\n - [No FEAR Act](/about-fda/jobs-and-training-fda/no-fear-act)\n - [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n\n\n\n\n\n - [FOIA](/regulatory-information/freedom-information)\n - [HHS.gov](https://www.hhs.gov/)\n - [USA.gov](https://www.usa.gov/)\n\n\n\n\n\n\n\n\n\n\n\n [Contact FDA](/about-fda/contact-fda) [Follow FDA on Facebook](https://www.facebook.com/FDA) [Follow FDA on X](https://x.com/FDA) [Follow FDA on Instagram](https://instagram.com/FDA)\n [Follow FDA on LinkedIn](https://www.linkedin.com/company/fda/) [View FDA videos on YouTube](https://youtube.com/@US_FDA) [Subscribe to FDA RSS feeds](/about-fda/contact-fda/subscribe-podcasts-and-news-feeds)\n\n [](/)\n\n Contact Number 1-888-INFO-FDA (1-888-463-6332)\n\n\n\n\n\n Back to Top",
"content_length": 12604,
"content_type": "text/html",
"description": "News & Events for Human Drugs",
"status_code": 200,
"success": true,
"title": "News & Events for Human Drugs | FDA",
"url": "https://www.fda.gov/drugs/news-events-human-drugs"
},
"error": "",
"elapsed": 0.219404626
}{
"tool_name": "web_fetch",
"tool_input": {
"brief": "Notable drug approvals list",
"max_age_seconds": 3600,
"url": "https://www.fda.gov/drugs/news-events-human-drugs/notable-approvals-drugs"
},
"dispatch_id": "toolu_bdrk_019awfz6UD3UFKELkfQDpRFu",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_fetch"
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_bdrk_019awfz6UD3UFKELkfQDpRFu",
"status": "running",
"result": null,
"error": "",
"elapsed": null,
"fields": {
"progress": {
"message": "Notable drug approvals list",
"metadata": {
"browser_chain": false,
"url": "https://www.fda.gov/drugs/news-events-human-drugs/notable-approvals-drugs"
}
},
"status": "running",
"updatedAt": 1789169309167
}
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_bdrk_019awfz6UD3UFKELkfQDpRFu",
"status": "completed",
"result": {
"content": "Notable Approvals | Drugs | FDA\n\n\n - [Skip to main content](#main-content)\n - [Skip to FDA Search](#search-form)\n - [Skip to in this section menu](#section-nav)\n - [Skip to footer links](#footer)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n  An official website of the United States government Here’s how you know\n\n\n\n\n\n \n\n\n\n**The .gov means it’s official.**\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.\n\n\n\n\n\n\n\n \n\n\n\n**The site is secure.**\n The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n [](/)\n\n\n\n\n - Search\n - Menu\n\n\n\n\n\n\n\n Search FDA Submit search\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Featured\n\n\n - [Report a Product Problem](https://contact.fda.gov/report-problem?utm_medium=%5BREDACTED%5D&utm_source=%5BREDACTED%5D)\n - [Contact FDA](/about-fda/contact-fda)\n - [FDA Guidance Documents](/regulatory-information/search-fda-guidance-documents)\n - [Recalls, Market Withdrawals and Safety Alerts](/safety/recalls-market-withdrawals-safety-alerts)\n - [Press Announcements](/news-events/newsroom/press-announcements)\n - [Warning Letters](/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\n - [Advisory Committees](/advisory-committees)\n - [En Español](/fda-en-espanol)\n\n\n\n\n\n\n\n\n\n\n\n## Products\n\n\n - [Food](/food)\n - [Drugs](/drugs)\n - [Medical Devices](/medical-devices)\n - [Radiation-Emitting Products](/radiation-emitting-products)\n - [Vaccines, Blood, and Biologics](/vaccines-blood-biologics)\n - [Animal and Veterinary](/animal-veterinary)\n - [Cosmetics](/cosmetics)\n - [Tobacco Products](/tobacco-products)\n\n\n\n\n\n\n\n## Topics\n\n\n - [About FDA](/about-fda)\n - [Combination Products](/combination-products)\n - [Regulatory Information](/regulatory-information)\n - [Safety](/safety)\n - [Emergency Preparedness](/emergency-preparedness-and-response)\n - [International Programs](/international-programs)\n - [News and Events](/news-events)\n - [Training and Continuing Education](/training-and-continuing-education)\n - [Inspections and Compliance](/inspections-compliance-enforcement-and-criminal-investigations)\n - [Science and Research](/science-research)\n\n\n\n\n\n\n\n## Information For\n\n\n - [Consumers](/consumers)\n - [Patients](/patients)\n - [Industry](/industry)\n - [Health Professionals](/health-professionals)\n - [Federal, State and Local Officials](/federal-state-local-tribal-and-territorial-officials)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Home](/)\n - [Drugs](/drugs)\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n - Notable Approvals | Drugs\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n\n\n\n [In this section](#section-nav)\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n - [Meetings, Conferences, & Workshops | Drugs](/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs)\n - [Q&A with FDA Podcast](/drugs/news-events-human-drugs/qa-fda-podcast)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [CDER Conversations](/drugs/news-events-human-drugs/cder-conversations)\n - [From Our Perspective](/drugs/news-events-human-drugs/our-perspective)\n - [Spotlight on CDER Science](/drugs/news-events-human-drugs/spotlight-cder-science)\n - [Things to Know About...](/drugs/news-events-human-drugs/things-know-about)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n# Notable Approvals | Drugs\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n - [Meetings, Conferences, & Workshops](/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs)\n - [Q&A with FDA Podcast](/drugs/news-events-human-drugs/qa-fda-podcast)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [CDER Conversations](/drugs/news-events-human-drugs/cder-conversations)\n - [From Our Perspective](/drugs/news-events-human-drugs/our-perspective)\n - [Spotlight on CDER Science](/drugs/news-events-human-drugs/spotlight-cder-science)\n - [Things to Know About...](/drugs/news-events-human-drugs/things-know-about)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n| Title | Date Posted | Brand Name | Active Ingredient |\n| [FDA Approves First Therapy to Target Muscle Loss in Spinal Muscular Atrophy](/drugs/news-events-human-drugs/fda-approves-first-therapy-target-muscle-loss-spinal-muscular-atrophy) | 9/11/2026 | Isembyld | apitegromab-mstn |\n| [FDA approves first treatment for children aged 4-11 years with APDS, a rare genetic disorder of the immune system](/drugs/news-events-human-drugs/fda-approves-first-treatment-children-aged-4-11-years-apds-rare-genetic-disorder-immune-system) | 9/11/2026 | Joenja | leniolisib |\n| [FDA Approves Treatment for Essential Thrombocythemia](/drugs/news-events-human-drugs/fda-approves-treatment-essential-thrombocythemia) | 8/31/2026 | Besremi | ropeginterferon alfa-2b-njft |\n| [FDA Approves Stelara for Pediatric Ulcerative Colitis](/drugs/news-events-human-drugs/fda-approves-stelara-pediatric-ulcerative-colitis) | 8/28/2026 | Stelara | ustekinumab |\n| [FDA Approves Drug to Treat HIV Infection in Newborns](/drugs/news-events-human-drugs/fda-approves-drug-treat-hiv-infection-newborns) | 8/25/2026 | Tivicay PD | dolutegravir |\n| [FDA Approves First Drug for Warm Autoimmune Hemolytic Anemia](/drugs/news-events-human-drugs/fda-approves-first-drug-warm-autoimmune-hemolytic-anemia) | 8/25/2026 | Imaavy | nipocalimab-aahu |\n| [FDA Approves Second Treatment for Fibrodysplasia Ossificans Progressiva](/drugs/news-events-human-drugs/fda-approves-second-treatment-fibrodysplasia-ossificans-progressiva) | 8/19/2026 | Pasatru | garetosmab-grts |\n| [FDA Approves First Nonprescription Fixed-Dose Combination of Acetaminophen and Naproxen Sodium for 12-Hour Pain Relief](/drugs/news-events-human-drugs/fda-approves-first-nonprescription-fixed-dose-combination-acetaminophen-and-naproxen-sodium-12-hour) | 7/24/2026 | Tylenol with Naproxen | acetaminophen and naproxen sodium |\n| [FDA Approves First Oral Therapy that Inhibits Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) to Lower Bad Cholesterol in Adults with High Cholesterol](/drugs/news-events-human-drugs/fda-approves-first-oral-therapy-inhibits-proprotein-convertase-subtilisinkexin-type-9-pcsk9-lower) | 7/16/2026 | Lipfendra | enlicitide |\n| [FDA Approves First At-home Starting Dose for Alzheimer’s Disease Treatment](/drugs/news-events-human-drugs/fda-approves-first-home-starting-dose-alzheimers-disease-treatment) | 7/13/2026 | Leqembi | lecanemab-irmb |\n| [FDA Approves New Treatment to Reduce Proteinuria in Adults with Primary Immunoglobulin A Nephropathy](/drugs/news-events-human-drugs/fda-approves-new-treatment-reduce-proteinuria-adults-primary-immunoglobulin-nephropathy) | 7/7/2026 | Trutakna | atacicept-vymj |\n| [FDA Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia](/drugs/news-events-human-drugs/fda-approves-first-treatment-shown-reduce-risk-acute-pancreatitis-adults-severe-hypertriglyceridemia) | 6/24/2026 | Tryngolza | olezarsen |\n| [FDA approves first oral carbapenem therapy for complicated urinary tract infections](/drugs/news-events-human-drugs/fda-approves-first-oral-carbapenem-therapy-complicated-urinary-tract-infections) | 6/17/2026 | Utebzi | tebipenem pivoxil |\n| [FDA Approves Drug for Pediatric Stage 3 Type I Diabetes](/drugs/news-events-human-drugs/fda-approves-drug-pediatric-stage-3-type-i-diabetes) | 6/12/2026 | Tzield | teplizumab |\n| [FDA approves first interchangeable biosimilars to Simponi and Simponi Aria (golimumab) to treat rheumatoid arthritis and ulcerative colitis](/drugs/news-events-human-drugs/fda-approves-first-interchangeable-biosimilars-simponi-and-simponi-aria-golimumab-treat-rheumatoid) | 5/15/2026 | Immgolis | golimumab-sldi |\n| [FDA approves drug for pediatric patients with most common form of dwarfism](/drugs/news-events-human-drugs/fda-approves-drug-pediatric-patients-most-common-form-dwarfism) | 3/4/2026 | Yuviwel | navepegritide |\n| [FDA approves drug for adult and pediatric patients aged 6 and older with allergic fungal rhinosinusitis](/drugs/news-events-human-drugs/fda-approves-drug-adult-and-pediatric-patients-aged-6-and-older-allergic-fungal-rhinosinusitis) | 2/24/2026 | Dupixent | dupilumab |\n| [FDA approves therapy for rare blood disorder in pediatric patients 12 years and older](/drugs/news-events-human-drugs/fda-approves-therapy-rare-blood-disorder-pediatric-patients-12-years-and-older) | 1/5/2026 | Cablivi | caplacizumab-yhdp |\n| [FDA approves first oral treatment for anemia in thalassemia, an inherited blood disorder](/drugs/news-events-human-drugs/fda-approves-first-oral-treatment-anemia-thalassemia-inherited-blood-disorder) | 1/5/2026 | Aqvesme | mitapivat |\n| [FDA approves first drug to treat serious complication of stem cell transplant](/drugs/news-events-human-drugs/fda-approves-first-drug-treat-serious-complication-stem-cell-transplant) | 1/5/2026 | Yartemlea | narsoplimab-wuug |\n| [FDA approves first prescription oral medicine for iron deficiency in pediatric patients ages 10 and older](/drugs/news-events-human-drugs/fda-approves-first-prescription-oral-medicine-iron-deficiency-pediatric-patients-ages-10-and-older) | 12/22/2025 | Accrufer | ferric maltol |\n| [FDA approves drug to improve functional capacity and symptoms in adults with rare inherited heart condition](/drugs/news-events-human-drugs/fda-approves-drug-improve-functional-capacity-and-symptoms-adults-rare-inherited-heart-condition) | 12/22/2025 | Myqorzo | aficamten |\n| [FDA approves drug to treat chronic, progressive lung disease](/drugs/news-events-human-drugs/fda-approves-drug-treat-chronic-progressive-lung-disease) | 12/19/2025 | Jascayd | nerandomilast |\n| [FDA approves drug for type of abnormally fast heart rhythm](/drugs/news-events-human-drugs/fda-approves-drug-type-abnormally-fast-heart-rhythm) | 12/15/2025 | Cardamyst | etripamil |\n| [FDA approves a new treatment for primary immunoglobulin A nephropathy](/drugs/news-events-human-drugs/fda-approves-new-treatment-primary-immunoglobulin-nephropathy) | 11/25/2025 | Voyxact | sibeprenlimab-szsi |\n| [FDA approves drug to reduce triglycerides in adults with familial chylomicronemia syndrome](/drugs/news-events-human-drugs/fda-approves-drug-reduce-triglycerides-adults-familial-chylomicronemia-syndrome) | 11/18/2025 | Redemplo | plozasiran |\n| [FDA approves first interchangeable biosimilar to Perjeta to treat certain types of breast cancer](/drugs/news-events-human-drugs/fda-approves-first-interchangeable-biosimilar-perjeta-treat-certain-types-breast-cancer) | 11/13/2025 | Poherdy | pertuzumab-dpzb |\n| [FDA approves 1st drug for children 7 years and older with irritable bowel syndrome with constipation](/drugs/news-events-human-drugs/fda-approves-1st-drug-children-7-years-and-older-irritable-bowel-syndrome-constipation) | 11/5/2025 | Linzess | linaclotide |\n| [FDA approves 1st drug for thymidine kinase 2 deficiency, a very rare mitochondrial disease](/drugs/news-events-human-drugs/fda-approves-1st-drug-thymidine-kinase-2-deficiency-very-rare-mitochondrial-disease) | 11/3/2025 | Kygevvi | doxecitine and doxribtimine |\n| [FDA approves drug to treat idiopathic pulmonary fibrosis](/drugs/news-events-human-drugs/fda-approves-drug-treat-idiopathic-pulmonary-fibrosis) | 10/7/2025 | Jascayd | nerandomilast |\n| [FDA approves new treatment for acromegaly, a rare endocrine disorder](/drugs/news-events-human-drugs/fda-approves-new-treatment-acromegaly-rare-endocrine-disorder) | 9/26/2025 | Palsonify | paltusotine |\n| [FDA approves drug to treat adults with persistent or chronic immune thrombocytopenia](/drugs/news-events-human-drugs/fda-approves-drug-treat-adults-persistent-or-chronic-immune-thrombocytopenia) | 9/2/2025 | Wayrilz | rilzabrutinib |\n| [FDA approves treatment for serious liver disease known as ‘MASH’](/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash) | 8/15/2025 | Wegovy | semaglutide |\n| [FDA approves first treatment for adults with complement 3 glomerulopathy, a rare kidney disease, to reduce proteinuria](/drugs/news-events-human-drugs/fda-approves-first-treatment-adults-complement-3-glomerulopathy-rare-kidney-disease-reduce) | 3/20/2025 | Fabhalta | iptacopan |\n| [FDA approves drug to prevent or reduce the frequency of bleeding episodes for patients with hemophilia A with inhibitors or hemophilia B with inhibitors](/drugs/news-events-human-drugs/fda-approves-drug-prevent-or-reduce-frequency-bleeding-episodes-patients-hemophilia-inhibitors-or) | 12/20/2024 | Alhemo | concizumab-mtci |\n| [FDA approves drug to reduce triglycerides in adult patients with familial chylomicronemia syndrome](/drugs/news-events-human-drugs/fda-approves-drug-reduce-triglycerides-adult-patients-familial-chylomicronemia-syndrome) | 12/19/2024 | Tryngolza | olezarsen |\n| [FDA approves drug for heart disorder caused by transthyretin-mediated amyloidosis](/drugs/news-events-human-drugs/fda-approves-drug-heart-disorder-caused-transthyretin-mediated-amyloidosis) | 11/25/2024 | Attruby | acoramidis |\n| [FDA approves new treatment for women with uncomplicated UTIs](https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-treatment-uncomplicated-urinary-tract-infections-adult-women-who-have-limited-or-no) | 10/23/2024 | Orlynvah | sulopenem etzadroxil and probenecid |\n| [FDA approves imaging drug for evaluation of myocardial ischemia and infarction](/drugs/news-events-human-drugs/fda-approves-imaging-drug-evaluation-myocardial-ischemia-and-infarction) | 9/27/2024 | Flyrcado | flurpiridaz F 18 |\n| [FDA approves new drug for hypoparathyroidism, a rare disorder](/drugs/news-events-human-drugs/fda-approves-new-drug-hypoparathyroidism-rare-disorder) | 8/12/2024 | Yorvipath | palopegteriparatide |\n| [FDA approves treatment for adults with Alzheimer’s disease](/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease) | 7/02/2024 | Kisunla | donanemab-azbt |\n| [FDA approves treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) in adults](/drugs/news-events-human-drugs/fda-approves-treatment-chronic-inflammatory-demyelinating-polyneuropathy-cidp-adults) | 6/24/2024 | Vyvgart Hytrulo | efgartigimod alfa and hyaluronidase-qvfc |\n| [FDA approves first interchangeable biosimilars to Eylea to treat macular degeneration and other eye conditions](/drugs/news-events-human-drugs/fda-approves-first-interchangeable-biosimilars-eylea-treat-macular-degeneration-and-other-eye) | 5/20/2024 | Yesafili and Opuviz | aflibercept-jbvf and aflibercept-yszy |\n| [FDA approves first drug for WHIM syndrome, a rare disorder](/drugs/news-events-human-drugs/fda-approves-first-drug-whim-syndrome-rare-disorder-can-lead-recurrent-life-threatening-infections) | 4/29/2024 | Xolremdi | mavorixafor |\n| [FDA approves imaging drug to assist in detection of cancerous tissue following lumpectomy](/drugs/news-events-human-drugs/fda-approves-imaging-drug-assist-detection-cancerous-tissue-following-lumpectomy) | 4/17/2024 | Lumisight | pegulicianine |\n| [FDA approves first interchangeable biosimilars to Prolia and Xgeva to treat certain types of osteoporosis and prevent bone events in cancer](/drugs/news-events-human-drugs/fda-approves-first-interchangeable-biosimilars-prolia-and-xgeva-treat-certain-types-osteoporosis-and) | 3/5/2024 | Jubbonti and Wyost | Denosumab-bbdz |\n| [FDA approves new drug under special pathway for patients receiving hemodialysis](/drugs/news-events-human-drugs/fda-approves-new-drug-under-special-pathway-patients-receiving-hemodialysis) | 11/15/2023 | Defencath | taurolidine and heparin |\n| [FDA approves first biosimilar to Actemra to treat adult and pediatric arthritis](/drugs/news-events-human-drugs/fda-approves-first-biosimilar-actemra-treat-adult-and-pediatric-arthritis) | 9/29/2023 | Tofidence | tocilizumab-bavi |\n| [FDA approves multiple generics of ADHD and BED treatment](/drugs/news-events-human-drugs/fda-approves-multiple-generics-adhd-and-bed-treatment) | 8/28/2023 | Vyvanse | lisdexamfetamine dimesylate |\n| [FDA approves first treatment for CD55-deficient protein-losing enteropathy (CHAPLE disease)](/drugs/news-events-human-drugs/fda-approves-first-treatment-cd55-deficient-protein-losing-enteropathy-chaple-disease) | 8/18/2023 | Veopoz | pozelimab-bbfg |\n| [FDA approves first treatment for Fibrodysplasia Ossificans Progressiva](/drugs/news-events-human-drugs/fda-approves-first-treatment-fibrodysplasia-ossificans-progressiva) | 8/17/2023 | Sohonos | palovarotene |\n| [FDA approves first treatment for molluscum contagiosum](/drugs/news-events-human-drugs/fda-approves-first-treatment-molluscum-contagiosum) | 7/24/2023 | Ycanth | cantharidin |\n| [FDA approves first treatment for pediatric functional constipation](/drugs/news-events-human-drugs/fda-approves-first-treatment-pediatric-functional-constipation) | 6/12/2023 | Linzess | linaclotide |\n| [FDA approves treatment for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma](/drugs/news-events-human-drugs/fda-approves-treatment-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-and-high-grade-b-cell) | 5/19/2023 | Epkinkly | epcoritamab-bysp |\n| [FDA approves first oral treatment for moderately to severely active Crohn’s disease](/drugs/news-events-human-drugs/fda-approves-first-oral-treatment-moderately-severely-active-crohns-disease) | 5/18/2023 | Rinvoq | upadacitinib |\n| [FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene](/drugs/news-events-human-drugs/fda-approves-treatment-amyotrophic-lateral-sclerosis-associated-mutation-sod1-gene) | 4/25/2023 | Qalsody | tofersen |\n| [FDA approves first treatment for activated phosphoinositide 3-kinase delta syndrome](/drugs/news-events-human-drugs/fda-approves-first-treatment-activated-phosphoinositide-3-kinase-delta-syndrome) | 3/24/2023 | Joenja | leniolisib |\n| [FDA approves first treatment for Rett Syndrome](/drugs/news-events-human-drugs/fda-approves-first-treatment-rett-syndrome) | 3/13/2023 | Daybue | trofinetide |\n| [FDA approves first treatment for Friedreich’s ataxia](/drugs/news-events-human-drugs/fda-approves-first-treatment-friedreichs-ataxia) | 2/28/2023 | Skyclarys | omaveloxolone |\n| [FDA approves first enzyme replacement therapy for rare alpha-mannosidosis](/drugs/news-events-human-drugs/fda-approves-first-enzyme-replacement-therapy-rare-alpha-mannosidosis) | 2/17/2023 | Lamzede | velmanase alfa-tycv |\n| [FDA approves drug combination treatment for adults with asthma](/drugs/news-events-human-drugs/fda-approves-drug-combination-treatment-adults-asthma) | 1/10/2023 | Airsupra | albuterol-budesonide |\n| [FDA approves imaging drug to help identify lung cancer lesions](/drugs/news-events-human-drugs/fda-approves-imaging-drug-help-identify-lung-lesions-during-surgery) | 12/16/2022 | Cytalux | pafolacianine |\n| [FDA approves first treatment for prurigo nodularis](/drugs/news-events-human-drugs/fda-approves-first-treatment-prurigo-nodularis) | 9/28/2022 | Dupixent | dupilumab |\n| [FDA approves treatment to improve kidney function in adults with hepatorenal syndrome](/drugs/news-events-human-drugs/fda-approves-treatment-improve-kidney-function-adults-hepatorenal-syndrome) | 9/14/2022 | Terlivaz | terlipressin |\n| [FDA approves topical treatment addressing repigmentation in vitiligo in patients aged 12 and older](/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older) | 7/19/2022 | Opzelura | ruxolitinib |\n| [FDA approves treatment for chronic weight management in pediatric patients aged 12 years and older](/drugs/news-events-human-drugs/fda-approves-treatment-chronic-weight-management-pediatric-patients-aged-12-years-and-older) | 6/24/2022 | Qsymia | phentermine and topiramate |\n| [FDA approves treatment for weight management in patients with Bardet-Biedl Syndrome aged 6 or older](/drugs/news-events-human-drugs/fda-approves-treatment-weight-management-patients-bardet-biedl-syndrome-aged-6-or-older) | 6/16/2022 | Imcivree | setmelanotide |\n| [FDA Approves Oral Form for the treatment of adults with amyotrophic lateral sclerosis (ALS)](/drugs/news-events-human-drugs/fda-approves-oral-form-treatment-adults-amyotrophic-lateral-sclerosis-als) | 5/12/2022 | Radicava ORS | edaravone |\n| [FDA approves new drug to improve heart function in adults with rare heart condition](/drugs/news-events-human-drugs/fda-approves-new-drug-improve-heart-function-adults-rare-heart-condition) | 4/29/2022 | Camzyos | mavacamten |\n| [FDA approves drug for treatment of seizures associated with rare disease in patients two years of age and older](/drugs/news-events-human-drugs/fda-approves-drug-treatment-seizures-associated-rare-disease-patients-two-years-age-and-older) | 3/18/2022 | Ztalmy | ganaxolone |\n| [FDA approves drug for adults with rare form of bone marrow disorder](/drugs/news-events-human-drugs/fda-approves-drug-adults-rare-form-bone-marrow-disorder) | 2/28/2022 | Vonjo | pacritinib |\n| [FDA approves treatment for anemia in adults with rare inherited disorder](/drugs/news-events-human-drugs/fda-approves-treatment-anemia-adults-rare-inherited-disorder) | 2/17/2022 | Pyrukynd | mitapivat |\n| [FDA approves treatment for adults with rare type of anemia](/drugs/news-events-human-drugs/fda-approves-treatment-adults-rare-type-anemia) | 2/4/2022 | Enjaymo | sutimlimab-jome |\n| [FDA approves add-on therapy to lower cholesterol among certain high-risk adults](/drugs/news-events-human-drugs/fda-approves-add-therapy-lower-cholesterol-among-certain-high-risk-adults) | 12/22/2021 | Leqvio | inclisiran |\n| [FDA approves drug to treat, help prevent types of blood clots in certain pediatric populations](/drugs/news-events-human-drugs/fda-approves-drug-treat-help-prevent-types-blood-clots-certain-pediatric-populations) | 12/20/2021 | Xarelto | rivaroxaban |\n| [FDA approves Tezspire as maintenance treatment for severe asthma](/drugs/news-events-human-drugs/fda-approves-maintenance-treatment-severe-asthma) | 12/17/2021 | Tezspire | tezepelumab-ekko |\n| [FDA approves drug to treat sickle cell disease in patients aged 4 up to 11 years](/drugs/news-events-human-drugs/fda-approves-drug-treat-sickle-cell-disease-patients-aged-4-11-years) | 12/17/2021 | Oxbryta | voxelotor |\n| [FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease](/drugs/fda-approves-first-drug-decrease-urine-protein-iga-nephropathy-rare-kidney-disease) | 12/15/2021 | Tarpeyo | budesonide |\n| [FDA approves naloxone injection to counteract opioid overdoses](/drugs/news-events-human-drugs/fda-approves-naloxone-injection-counteract-opioid-overdoses) | 10/15/2021 | ZIMHI | naloxone hydrochloride |\n| [FDA approves add-on drug for adults with rare form of blood vessel inflammation](/drugs/news-events-human-drugs/fda-approves-add-drug-adults-rare-form-blood-vessel-inflammation) | 10/13/2021 | Tavneos | avacopan |\n| [FDA approves add-on drug for ages 10 & up with rare forms of high cholesterol](/drugs/news-events-human-drugs/fda-approves-add-drug-ages-10-rare-forms-high-cholesterol) | 9/24/2021 | Repatha | evolocumab |\n| [FDA approves new use of transplant drug based on real-world evidence](/drugs/news-events-human-drugs/fda-approves-new-use-transplant-drug-based-real-world-evidence) | 7/16/2021 | Prograf | tacrolimus |\n| [FDA approves drug to reduce risk of serious kidney and heart complications in adults with chronic kidney disease associated with type 2 diabetes](/drugs/news-events-human-drugs/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease) | 7/9/2021 | Kerendia | finerenone |\n| [FDA approves therapy for pediatric patients with serious rare blood disease](/drugs/news-events-human-drugs/fda-approves-therapy-pediatric-patients-serious-rare-blood-disease) | 6/7/2021 | Ultomiris | ravulizumab-cwvz |\n| [FDA approves drug to treat smallpox](/drugs/news-events-human-drugs/fda-approves-drug-treat-smallpox) | 6/4/2021 | Tembexa | brincidofovir |\n| [FDA approves second PSMA-targeted PET imaging drug for men with prostate cancer](/drugs/news-events-human-drugs/fda-approves-second-psma-targeted-pet-imaging-drug-men-prostate-cancer) | 5/27/2021 | Pylarify | piflufolastat F 18 |\n| [FDA approves new treatment for adults with serious rare blood disease](/drugs/news-events-human-drugs/fda-approves-new-treatment-adults-serious-rare-blood-disease) | 5/14/2021 | Empaveli | pegcetacoplan |\n| [FDA approves add-on therapy for patients with genetic form of severely high cholesterol](/drugs/news-events-human-drugs/fda-approves-add-therapy-patients-genetic-form-severely-high-cholesterol) | 4/1/2021 | Praluent | alirocumab |\n| [FDA approves first treatment for disease that causes recurrent inflammation in sac surrounding heart](/drugs/news-events-human-drugs/fda-approves-first-treatment-disease-causes-recurrent-inflammation-sac-surrounding-heart) | 3/18/2021 | Arcalyst | rilonacept |\n| [FDA approves add-on therapy for patients with genetic form of severely high cholesterol](/drugs/news-events-human-drugs/fda-approves-add-therapy-patients-genetic-form-severely-high-cholesterol-0) | 2/11/2021 | Evkeeza | evinacumab-dgnb |\n| [FDA approves treatment for ebola virus](/drugs/news-events-human-drugs/fda-approves-treatment-ebola-virus) | 12/21/2020 | Ebanga | Ansuvimab-zykl |\n| [FDA approves weight management drug for patients aged 12 and older](/drugs/news-events-human-drugs/fda-approves-weight-management-drug-patients-aged-12-and-older) | 12/4/2020 | Saxenda | liraglutide |\n| [FDA approves first treatment for weight management for people with certain rare genetic conditions](/drugs/news-events-human-drugs/fda-approves-first-treatment-weight-management-people-certain-rare-genetic-conditions) | 11/27/2020 | Imcivree | setmelanotide |\n| [FDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—the science of safety and effectiveness](/drugs/news-events-human-drugs/fdas-approval-veklury-remdesivir-treatment-covid-19-science-safety-and-effectiveness) | 10/22/2020 | Veklury | remdesivir |\n| [FDA approves weekly therapy for adult growth hormone deficiency](/drugs/news-events-human-drugs/fda-approves-weekly-therapy-adult-growth-hormone-deficiency) | 9/1/2020 | Sogroya | somapacitan |\n| [FDA approves new treatment for rare hereditary disease](/drugs/news-events-human-drugs/fda-approves-new-treatment-rare-hereditary-disease) | 8/23/2018 | Takhzyro | lanadelumab |\n\n\n\n\n\n\n\n\n -\n\n\n\n## Content current as of:\n\n\n\n09/11/2026\n\n\n\n\n -\n\n\n\n## Regulated Product(s)\n\n\n - Drugs\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Feedback\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [FDA Archive](/about-fda/about-website/fdagov-archive)\n - [About FDA](/about-fda)\n - [Accessibility](/about-fda/about-website/internet-accessibility)\n\n\n\n\n\n\n - [Visitor Information](/about-fda/visitor-information)\n - [Website Policies / Privacy](/about-fda/about-website/website-policies)\n - [No FEAR Act](/about-fda/jobs-and-training-fda/no-fear-act)\n - [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n\n\n\n\n\n - [FOIA](/regulatory-information/freedom-information)\n - [HHS.gov](https://www.hhs.gov/)\n - [USA.gov](https://www.usa.gov/)\n\n\n\n\n\n\n\n\n\n\n\n [Contact FDA](/about-fda/contact-fda) [Follow FDA on Facebook](https://www.facebook.com/FDA) [Follow FDA on X](https://x.com/FDA) [Follow FDA on Instagram](https://instagram.com/FDA)\n [Follow FDA on LinkedIn](https://www.linkedin.com/company/fda/) [View FDA videos on YouTube](https://youtube.com/@US_FDA) [Subscribe to FDA RSS feeds](/about-fda/contact-fda/subscribe-podcasts-and-news-feeds)\n\n [](/)\n\n Contact Number 1-888-INFO-FDA (1-888-463-6332)\n\n\n\n\n\n Back to Top",
"content_length": 28223,
"content_type": "text/html",
"description": "News about human drug-related approvals",
"status_code": 200,
"success": true,
"title": "Notable Approvals | Drugs | FDA",
"url": "https://www.fda.gov/drugs/news-events-human-drugs/notable-approvals-drugs"
},
"error": "",
"elapsed": 0.044887865
}{
"tool_name": "web_fetch",
"tool_input": {
"brief": "Novel drug approvals 2026 list",
"max_age_seconds": 3600,
"url": "https://www.fda.gov/drugs/development-approval-process-drugs/novel-drug-approvals-fda"
},
"dispatch_id": "toolu_bdrk_01Nu8aLh1dNMfnZX4cXbJNtM",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_fetch"
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_bdrk_01Nu8aLh1dNMfnZX4cXbJNtM",
"status": "running",
"result": null,
"error": "",
"elapsed": null,
"fields": {
"progress": {
"message": "Novel drug approvals 2026 list",
"metadata": {
"browser_chain": false,
"url": "https://www.fda.gov/drugs/development-approval-process-drugs/novel-drug-approvals-fda"
}
},
"status": "running",
"updatedAt": 1789169309171
}
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_bdrk_01Nu8aLh1dNMfnZX4cXbJNtM",
"status": "completed",
"result": {
"content": "Novel Drug Approvals at FDA | FDA\n\n\n - [Skip to main content](#main-content)\n - [Skip to FDA Search](#search-form)\n - [Skip to in this section menu](#section-nav)\n - [Skip to footer links](#footer)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n  An official website of the United States government Here’s how you know\n\n\n\n\n\n \n\n\n\n**The .gov means it’s official.**\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.\n\n\n\n\n\n\n\n \n\n\n\n**The site is secure.**\n The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n [](/)\n\n\n\n\n - Search\n - Menu\n\n\n\n\n\n\n\n Search FDA Submit search\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Featured\n\n\n - [Report a Product Problem](https://contact.fda.gov/report-problem?utm_medium=%5BREDACTED%5D&utm_source=%5BREDACTED%5D)\n - [Contact FDA](/about-fda/contact-fda)\n - [FDA Guidance Documents](/regulatory-information/search-fda-guidance-documents)\n - [Recalls, Market Withdrawals and Safety Alerts](/safety/recalls-market-withdrawals-safety-alerts)\n - [Press Announcements](/news-events/newsroom/press-announcements)\n - [Warning Letters](/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\n - [Advisory Committees](/advisory-committees)\n - [En Español](/fda-en-espanol)\n\n\n\n\n\n\n\n\n\n\n\n## Products\n\n\n - [Food](/food)\n - [Drugs](/drugs)\n - [Medical Devices](/medical-devices)\n - [Radiation-Emitting Products](/radiation-emitting-products)\n - [Vaccines, Blood, and Biologics](/vaccines-blood-biologics)\n - [Animal and Veterinary](/animal-veterinary)\n - [Cosmetics](/cosmetics)\n - [Tobacco Products](/tobacco-products)\n\n\n\n\n\n\n\n## Topics\n\n\n - [About FDA](/about-fda)\n - [Combination Products](/combination-products)\n - [Regulatory Information](/regulatory-information)\n - [Safety](/safety)\n - [Emergency Preparedness](/emergency-preparedness-and-response)\n - [International Programs](/international-programs)\n - [News and Events](/news-events)\n - [Training and Continuing Education](/training-and-continuing-education)\n - [Inspections and Compliance](/inspections-compliance-enforcement-and-criminal-investigations)\n - [Science and Research](/science-research)\n\n\n\n\n\n\n\n## Information For\n\n\n - [Consumers](/consumers)\n - [Patients](/patients)\n - [Industry](/industry)\n - [Health Professionals](/health-professionals)\n - [Federal, State and Local Officials](/federal-state-local-tribal-and-territorial-officials)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Home](/)\n - [Drugs](/drugs)\n - [Development & Approval Process | Drugs](/drugs/development-approval-process-drugs)\n - Novel Drug Approvals at FDA\n\n\n - [Development & Approval Process | Drugs](/drugs/development-approval-process-drugs)\n\n\n\n\n\n\n\n [In this section](#section-nav)\n\n\n - [Novel Drug Approvals at FDA](/drugs/development-approval-process-drugs/novel-drug-approvals-fda)\n\n\n\n\n - [Novel Drug Approvals for 2026](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)\n - [Novel Drug Approvals for 2025](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)\n - [Novel Drug Approvals for 2024](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)\n - [Novel Drug Approvals for 2023](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)\n - [Novel Drug Approvals for 2022](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022)\n - [Novel Drug Approvals for 2021](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n# Novel Drug Approvals at FDA\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Novel Drug Approvals at FDA](/drugs/development-approval-process-drugs/novel-drug-approvals-fda)\n\n\n\n\n - [Novel Drug Approvals for 2026](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)\n - [Novel Drug Approvals for 2025](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)\n - [Novel Drug Approvals for 2024](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)\n - [Novel Drug Approvals for 2023](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)\n - [Novel Drug Approvals for 2022](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022)\n - [Novel Drug Approvals for 2021](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n## What are \"Novel\" Drugs?\n\n\"Novel\" drugs are new drugs never before approved or marketed in the U.S. See [Drugs@FDA](https://www.accessdata.fda.gov/scripts/cder/daf/) for information about all of CDER’s approved drugs and biological products. \n\n## Helping Guide the Way for New Medicines\n\nInnovative drugs often mean new treatment options for patients and advances in health care for the American public. When it comes the development of new drugs and therapeutic biological products, FDA’s Center for Drug Evaluation and Research (CDER) provides clarity to drug developers on the necessary study design elements and other data needed in the drug application to support a full and comprehensive assessment. To do so, CDER relies on its understanding of the science used to create new products, testing and manufacturing procedures, and the diseases and conditions that new products are designed to treat. \n\n## A Wide Range of Products\n\nEach year, CDER approves a wide range of new drugs and biological products: \n\n- Some of these products have never been used in clinical practice. Below is a listing of new molecular entities and new therapeutic biological products approved by CDER and organized by calendar year. This listing does not contain vaccines, allergenic products, blood and blood products, plasma derivatives, cellular and gene therapy products, or other products approved by the [Center for Biologics Evaluation and Research](/vaccines-blood-biologics/development-approval-process-cber/biological-approvals-year).\n- Others are the same as, or related to, previously approved products, and they will compete with those products in the marketplace. See [Drugs@FDA](https://www.accessdata.fda.gov/scripts/cder/daf/) for information about all of CDER’s approved drugs and biological products. \n\n## New Molecular Entities (NMEs)\n\nCertain drugs are classified as new molecular entities (“NMEs”) for purposes of FDA review. Many of these products contain active moieties that FDA had not previously approved, either as a single ingredient drug or as part of a combination product. These products frequently provide important new therapies for patients. Some drugs are characterized as NMEs for administrative purposes, but nonetheless contain active moieties that are closely related to active moieties in products that FDA has previously approved. FDA’s classification of a drug as an “NME” for review purposes is distinct from FDA’s determination of whether a drug product is a “new chemical entity” or “NCE” within the meaning of the Federal Food, Drug, and Cosmetic Act. \n\n**2015-2020 Reports are available in the **[FDA Archive](https://web.archive.org/web/20240418171144/https://www.fda.gov/drugs/development-approval-process-drugs/novel-drug-approvals-fda)\n\n## New Molecular Entity and New Therapeutic Biological Product Approvals (CDER only)\n\n- [Novel Drug Approvals for 2026](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)\n- [Novel Drug Approvals for 2025](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)\n- [Novel Drug Approvals for 2024](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)\n- [Novel Drug Approvals for 2023](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)\n- [Novel Drug Approvals for 2022](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022)\n- [Novel Drug Approvals for 2021](/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021)\n\n## Drug Approval Information (CDER only)\n\n- [Recent New and Generic Drug Approvals](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=%5BREDACTED%5D)\n- [Drug Approval Reports by Month](http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=%5BREDACTED%5D)\n- [Drug and Biologic Approval and IND Activity Reports](/drugs/how-drugs-are-developed-and-approved/drug-and-biologic-approval-and-ind-activity-reports)\n\n## Related Information from Other FDA Centers\n\n- [Innovation and Regulatory Science (CBER)](/vaccines-blood-biologics/science-research-biologics/innovation-and-regulatory-science)\n\n## Resources\n\n- [Compilation of CDER New Molecular Entity (NME) Drug and New Biologic Approvals](/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals)\n- [Prescribing Information Resources](/node/356177)\n- [Frequently Asked Questions: Breakthrough Therapies](/regulatory-information/food-and-drug-administration-safety-and-innovation-act-fdasia/frequently-asked-questions-breakthrough-therapies)\n- [Critical Path Innovation Meetings (CPIM)](/drugs/drug-innovation/critical-path-innovation-meetings-cpim)\n - [CPIM FAQ's](/drugs/drug-innovation/critical-path-innovation-meeting-cpim-faqs)\n - [CPIM Topics Held to Date](/drugs/drug-innovation/critical-path-innovation-meeting-cpim-topics-held-date)\n\n\n\n\n\n\n\n\n\n -\n\n\n\n## Content current as of:\n\n\n\n07/21/2026\n\n\n\n\n -\n\n\n\n## Regulated Product(s)\n\n\n - Drugs\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Feedback\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [FDA Archive](/about-fda/about-website/fdagov-archive)\n - [About FDA](/about-fda)\n - [Accessibility](/about-fda/about-website/internet-accessibility)\n\n\n\n\n\n\n - [Visitor Information](/about-fda/visitor-information)\n - [Website Policies / Privacy](/about-fda/about-website/website-policies)\n - [No FEAR Act](/about-fda/jobs-and-training-fda/no-fear-act)\n - [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n\n\n\n\n\n - [FOIA](/regulatory-information/freedom-information)\n - [HHS.gov](https://www.hhs.gov/)\n - [USA.gov](https://www.usa.gov/)\n\n\n\n\n\n\n\n\n\n\n\n [Contact FDA](/about-fda/contact-fda) [Follow FDA on Facebook](https://www.facebook.com/FDA) [Follow FDA on X](https://x.com/FDA) [Follow FDA on Instagram](https://instagram.com/FDA)\n [Follow FDA on LinkedIn](https://www.linkedin.com/company/fda/) [View FDA videos on YouTube](https://youtube.com/@US_FDA) [Subscribe to FDA RSS feeds](/about-fda/contact-fda/subscribe-podcasts-and-news-feeds)\n\n [](/)\n\n Contact Number 1-888-INFO-FDA (1-888-463-6332)\n\n\n\n\n\n Back to Top",
"content_length": 10795,
"content_type": "text/html",
"description": "Innovation drives progress. When it comes to innovation in the development of new drugs and therapeutic biological products, FDA’s Center for Drug Evaluation and Research (CDER) supports the pharmaceutical industry at every step of the process.",
"status_code": 200,
"success": true,
"title": "Novel Drug Approvals at FDA | FDA",
"url": "https://www.fda.gov/drugs/development-approval-process-drugs/novel-drug-approvals-fda"
},
"error": "",
"elapsed": 0.086415955
}{
"tool_name": "web_fetch",
"tool_input": {
"brief": "RSS feed of what's new related to drugs",
"max_age_seconds": 3600,
"url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/drugs/rss.xml"
},
"dispatch_id": "toolu_bdrk_016Mbw1w4G44tja41KvsBGo4",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_fetch"
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_bdrk_016Mbw1w4G44tja41KvsBGo4",
"status": "running",
"result": null,
"error": "",
"elapsed": null,
"fields": {
"progress": {
"message": "RSS feed of what's new related to drugs",
"metadata": {
"browser_chain": false,
"url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/drugs/rss.xml"
}
},
"status": "running",
"updatedAt": 1789169309174
}
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_bdrk_016Mbw1w4G44tja41KvsBGo4",
"status": "completed",
"result": {
"content": "<?xml version=\"1.0\" encoding=\"utf-8\"?>\n<rss xmlns:dc=\"http://purl.org/dc/elements/1.1/\" version=\"2.0\" xml:base=\"http://www.fda.gov/\">\n <channel>\n <title>What's New: Drugs RSS Feed</title>\n <link>http://www.fda.gov/</link>\n <description/>\n <language>en</language>\n \n <item>\n <title>Novel Drug Approvals for 2026</title>\n <link>http://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</link>\n <description>FDA Novel Drug Therapy Approvals for 2026</description>\n <pubDate>Fri, 11 Sep 2026 17:40:58 EDT</pubDate>\n <dc:creator>FDA</dc:creator>\n <guid isPermaLink=\"true\">http://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026</guid>\n </item>\n<item>\n <title>Notable Approvals | Drugs</title>\n <link>http://www.fda.gov/drugs/news-events-human-drugs/notable-approvals-drugs</link>\n <description>News about human drug-related approvals</description>\n <pubDate>Fri, 11 Sep 2026 17:27:47 EDT</pubDate>\n <dc:creator>FDA</dc:creator>\n <guid isPermaLink=\"true\">http://www.fda.gov/drugs/news-events-human-drugs/notable-approvals-drugs</guid>\n </item>\n<item>\n <title>Rare Disease Drug Approvals </title>\n <link>http://www.fda.gov/about-fda/accelerating-rare-disease-cures-arc-program/rare-disease-drug-approvals</link>\n <description>This page describes recent rare disease drug approvals that received a CDER or FDA communication. This is not an exhaustive list of all rare disease drug approvals.</description>\n <pubDate>Fri, 11 Sep 2026 17:25:06 EDT</pubDate>\n <dc:creator>FDA</dc:creator>\n <guid isPermaLink=\"true\">http://www.fda.gov/about-fda/accelerating-rare-disease-cures-arc-program/rare-disease-drug-approvals</guid>\n </item>\n<item>\n <title>What's New Related to Drugs</title>\n <link>http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs</link>\n <description>Want to know what's new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.</description>\n <pubDate>Fri, 11 Sep 2026 17:19:52 EDT</pubDate>\n <dc:creator>FDA</dc:creator>\n <guid isPermaLink=\"true\">http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs</guid>\n </item>\n<item>\n <title>FDA Approves First Therapy to Target Muscle Loss in Spinal Muscular Atrophy</title>\n <link>http://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-therapy-target-muscle-loss-spinal-muscular-atrophy</link>\n <description>The U.S. Food and Drug Administration today approved Isembyld (apitegromab-mstn) injection to treat spinal muscular atrophy (SMA) in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment. Isembyld is the first therapy approved for SMA that dire</description>\n <pubDate>Fri, 11 Sep 2026 17:18:23 EDT</pubDate>\n <dc:creator>FDA</dc:creator>\n <guid isPermaLink=\"true\">http://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-therapy-target-muscle-loss-spinal-muscular-atrophy</guid>\n </item>\n<item>\n <title>CDER Small Business & Industry Assistance (SBIA)</title>\n <link>http://www.fda.gov/drugs/development-approval-process-drugs/cder-small-business-industry-assistance-sbia</link>\n <description>A Comprehensive Resource for Information on Human Drug Development in Regulation </description>\n <pubDate>Fri, 11 Sep 2026 13:28:11 EDT</pubDate>\n <dc:creator>FDA</dc:creator>\n <guid isPermaLink=\"true\">http://www.fda.gov/drugs/development-approval-process-drugs/cder-small-business-industry-assistance-sbia</guid>\n </item>\n<item>\n <title>Advancing Generic Drug Development: Modernizing Bioequivalence Approaches for Topical & Transdermal Products - 09/10/2026</title>\n <link>http://www.fda.gov/drugs/news-events-human-drugs/advancing-generic-drug-development-modernizing-bioequivalence-approaches-topical-transdermal</link>\n <description>This half-day virtual workshop features FDA expert presentations and audience Q&amp;A on bioequivalence (BE) approaches for topical and transdermal generic drug products.</description>\n <pubDate>Fri, 11 Sep 2026 13:27:56 EDT</pubDate>\n <dc:creator>FDA</dc:creator>\n <guid isPermaLink=\"true\">http://www.fda.gov/drugs/news-events-human-drugs/advancing-generic-drug-development-modernizing-bioequivalence-approaches-topical-transdermal</guid>\n </item>\n<item>\n <title>Eco-NAMs Webinar Series | QSARs to Predict Aquatic Toxicity - 09/17/2026</title>\n <link>http://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/eco-nams-webinar-series-qsars-predict-aquatic-toxicity-09172026</link>\n <description>The Eco-NAMs Webinar Series aims to present the most informative and up-to-date science on new approach methodologies (NAMs) for ecotoxicity assessments</description>\n <pubDate>Fri, 11 Sep 2026 12:16:16 EDT</pubDate>\n <dc:creator>FDA</dc:creator>\n <guid isPermaLink=\"true\">http://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/eco-nams-webinar-series-qsars-predict-aquatic-toxicity-09172026</guid>\n </item>\n<item>\n <title>FDA approves first treatment for children aged 4-11 years with APDS, a rare genetic disorder of the immune system</title>\n <link>http://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-children-aged-4-11-years-apds-rare-genetic-disorder-immune-system</link>\n <description>FDA has approved Joenja (leniolisib) tablets as the first treatment for activated phosphoinositide 3-kinase delta syndrome in children 4-11 years who weigh at least 27 kg. Joenja was first approved in 2023 for the same indication in patients 12 years and older at a dose of 70 mg orally twice a day. </description>\n <pubDate>Fri, 11 Sep 2026 11:55:21 EDT</pubDate>\n <dc:creator>FDA</dc:creator>\n <guid isPermaLink=\"true\">http://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-children-aged-4-11-years-apds-rare-genetic-disorder-immune-system</guid>\n </item>\n<item>\n <title>Generic Drug Facilities, Sites and Organization Lists</title>\n <link>http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists</link>\n <description>Generic Drug Facilities, Sites and Organization Lists</description>\n <pubDate>Fri, 11 Sep 2026 11:36:35 EDT</pubDate>\n <dc:creator>FDA</dc:creator>\n <guid isPermaLink=\"true\">http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists</guid>\n </item>\n<item>\n <title>Drugs@FDA Data Files</title>\n <link>http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files</link>\n <description>Drugs@FDA Downloadable Data File in ZIP format, Data Definitions, and Entity Relationship Diagram (ERD)</description>\n <pubDate>Fri, 11 Sep 2026 08:59:54 EDT</pubDate>\n <dc:creator>FDA</dc:creator>\n <guid isPermaLink=\"true\">http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files</guid>\n </item>\n<item>\n <title>Rare Diseases at FDA</title>\n <link>http://www.fda.gov/patients/rare-diseases-fda</link>\n <description>The FDA works with many people and groups, such as patients, caregivers, and drug and device manufactures, to support rare disease product development. </description>\n <pubDate>Thu, 10 Sep 2026 14:46:03 EDT</pubDate>\n <dc:creator>FDA</dc:creator>\n <guid isPermaLink=\"true\">http://www.fda.gov/patients/rare-diseases-fda</guid>\n </item>\n<item>\n <title>Tips to Stay Safe in the Sun: From Sunscreen to Sunglasses</title>\n <link>http://www.fda.gov/consumers/consumer-updates/tips-stay-safe-sun-sunscreen-sunglasses</link>\n <description>Sun safety is always in season. It’s important to protect your skin from sun damage throughout the year, no matter the weather. The FDA continues to evaluate sunscreen products to ensure that their active ingredients are safe and effective.</description>\n <pubDate>Thu, 10 Sep 2026 14:38:35 EDT</pubDate>\n <dc:creator>FDA</dc:creator>\n <guid isPermaLink=\"true\">http://www.fda.gov/consumers/consumer-updates/tips-stay-safe-sun-sunscreen-sunglasses</guid>\n </item>\n<item>\n <title>Should You Put Sunscreen on Infants? Not Usually</title>\n <link>http://www.fda.gov/consumers/consumer-updates/should-you-put-sunscreen-infants-not-usually</link>\n <description>Your infant’s sensitive skin is vulnerable to serious burns. But sunscreen isn’t the answer. Infants are at greater risk than adults of sunscreen side effects, such as a rash. The FDA recommends keeping newborns and babies younger than 6 months out of direct sunlight.</description>\n <pubDate>Thu, 10 Sep 2026 14:38:32 EDT</pubDate>\n <dc:creator>FDA</dc:creator>\n <guid isPermaLink=\"true\">http://www.fda.gov/consumers/consumer-updates/should-you-put-sunscreen-infants-not-usually</guid>\n </item>\n<item>\n <title>Reviews of Pediatric Studies Conducted under BPCA and Pediatric assessments conducted under PREA from 2012 – present</title>\n <link>http://www.fda.gov/drugs/development-resources/reviews-pediatric-studies-conducted-under-bpca-and-pediatric-assessments-conducted-under-prea-2012</link>\n <description>The following are the medical, statistical, and clinical pharmacology reviews of pediatric studies conducted in response to a Written Request issued under the BPCA and pediatric assessments conducted under PREA.</description>\n <pubDate>Thu, 10 Sep 2026 13:51:15 EDT</pubDate>\n <dc:creator>FDA</dc:creator>\n <guid isPermaLink=\"true\">http://www.fda.gov/drugs/development-resources/reviews-pediatric-studies-conducted-under-bpca-and-pediatric-assessments-conducted-under-prea-2012</guid>\n </item>\n<item>\n <title>FDA Rare Disease Innovation Hub</title>\n <link>http://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/fda-rare-disease-innovation-hub</link>\n <description>FDA created the Rare Disease Innovation Hub (the Hub) to serve as a point of collaboration and connectivity between CBER and CDER with the goal of ultimately improving outcomes for patients.</description>\n <pubDate>Thu, 10 Sep 2026 13:39:23 EDT</pubDate>\n <dc:creator>FDA</dc:creator>\n <guid isPermaLink=\"true\">http://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/fda-rare-disease-innovation-hub</guid>\n </item>\n<item>\n <title>Drug Compliance Programs</title>\n <link>http://www.fda.gov/drugs/guidance-compliance-regulatory-information/drug-compliance-programs</link>\n <description>FDA compliance programs provide guidance and instructions to FDA staff for obtaining information to help fulfill agency plans in the specified program area. </description>\n <pubDate>Thu, 10 Sep 2026 12:52:21 EDT</pubDate>\n <dc:creator>FDA</dc:creator>\n <guid isPermaLink=\"true\">http://www.fda.gov/drugs/guidance-compliance-regulatory-information/drug-compliance-programs</guid>\n </item>\n<item>\n <title>Jobs in Oncology/Hematology</title>\n <link>http://www.fda.gov/about-fda/scientific-careers-fda/jobs-oncologyhematology</link>\n <description>FDA's Office of Hematology Oncology Products is recruiting Medical Oncologists to serve in the dynamic, highly challenging, and innovative atmosphere of oncology drug development and research.</description>\n <pubDate>Thu, 10 Sep 2026 12:46:23 EDT</pubDate>\n <dc:creator>FDA</dc:creator>\n <guid isPermaLink=\"true\">http://www.fda.gov/about-fda/scientific-careers-fda/jobs-oncologyhematology</guid>\n </item>\n<item>\n <title> Questions and Answers: FDA’s regulatory actions on over-the-counter sunscreen</title>\n <link>http://www.fda.gov/drugs/understanding-over-counter-medicines/questions-and-answers-fdas-regulatory-actions-over-counter-sunscreen</link>\n <description>The following questions and answers provide more information on FDA’s regulatory actions on over-the-counter sunscreen.</description>\n <pubDate>Thu, 10 Sep 2026 10:26:46 EDT</pubDate>\n <dc:creator>FDA</dc:creator>\n <guid isPermaLink=\"true\">http://www.fda.gov/drugs/understanding-over-counter-medicines/questions-and-answers-fdas-regulatory-actions-over-counter-sunscreen</guid>\n </item>\n<item>\n <title>Sunscreen: How to Help Protect Your Skin from the Sun</title>\n <link>http://www.fda.gov/drugs/understanding-over-counter-medicines/sunscreen-how-help-protect-your-skin-sun</link>\n <description>How you use sunscreens, and what other protective measures you take, make a difference in how well you are able to protect yourself and your family from sunburn, skin cancer, early skin aging and other risks of overexposure to the sun.</description>\n <pubDate>Thu, 10 Sep 2026 10:25:30 EDT</pubDate>\n <dc:creator>FDA</dc:creator>\n <guid isPermaLink=\"true\">http://www.fda.gov/drugs/understanding-over-counter-medicines/sunscreen-how-help-protect-your-skin-sun</guid>\n </item>\n\n </channel>\n</rss>\n",
"content_length": 12846,
"content_type": "application/rss+xml",
"description": "",
"status_code": 200,
"success": true,
"title": "",
"url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/drugs/rss.xml"
},
"error": "",
"elapsed": 0.029072682
}{
"tool_name": "web_fetch",
"tool_input": {
"brief": "What's new related to drugs, recent items",
"max_age_seconds": 3600,
"url": "https://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs"
},
"dispatch_id": "toolu_bdrk_01RdXMZYDi4XTJurqC61uYqR",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_fetch"
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_bdrk_01RdXMZYDi4XTJurqC61uYqR",
"status": "running",
"result": null,
"error": "",
"elapsed": null,
"fields": {
"progress": {
"message": "What's new related to drugs, recent items",
"metadata": {
"browser_chain": false,
"url": "https://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs"
}
},
"status": "running",
"updatedAt": 1789169309176
}
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_bdrk_01RdXMZYDi4XTJurqC61uYqR",
"status": "completed",
"result": {
"content": "What's New Related to Drugs | FDA\n\n\n - [Skip to main content](#main-content)\n - [Skip to FDA Search](#search-form)\n - [Skip to in this section menu](#section-nav)\n - [Skip to footer links](#footer)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n  An official website of the United States government Here’s how you know\n\n\n\n\n\n \n\n\n\n**The .gov means it’s official.**\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.\n\n\n\n\n\n\n\n \n\n\n\n**The site is secure.**\n The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n [](/)\n\n\n\n\n - Search\n - Menu\n\n\n\n\n\n\n\n Search FDA Submit search\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Featured\n\n\n - [Report a Product Problem](https://contact.fda.gov/report-problem?utm_medium=%5BREDACTED%5D&utm_source=%5BREDACTED%5D)\n - [Contact FDA](/about-fda/contact-fda)\n - [FDA Guidance Documents](/regulatory-information/search-fda-guidance-documents)\n - [Recalls, Market Withdrawals and Safety Alerts](/safety/recalls-market-withdrawals-safety-alerts)\n - [Press Announcements](/news-events/newsroom/press-announcements)\n - [Warning Letters](/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\n - [Advisory Committees](/advisory-committees)\n - [En Español](/fda-en-espanol)\n\n\n\n\n\n\n\n\n\n\n\n## Products\n\n\n - [Food](/food)\n - [Drugs](/drugs)\n - [Medical Devices](/medical-devices)\n - [Radiation-Emitting Products](/radiation-emitting-products)\n - [Vaccines, Blood, and Biologics](/vaccines-blood-biologics)\n - [Animal and Veterinary](/animal-veterinary)\n - [Cosmetics](/cosmetics)\n - [Tobacco Products](/tobacco-products)\n\n\n\n\n\n\n\n## Topics\n\n\n - [About FDA](/about-fda)\n - [Combination Products](/combination-products)\n - [Regulatory Information](/regulatory-information)\n - [Safety](/safety)\n - [Emergency Preparedness](/emergency-preparedness-and-response)\n - [International Programs](/international-programs)\n - [News and Events](/news-events)\n - [Training and Continuing Education](/training-and-continuing-education)\n - [Inspections and Compliance](/inspections-compliance-enforcement-and-criminal-investigations)\n - [Science and Research](/science-research)\n\n\n\n\n\n\n\n## Information For\n\n\n - [Consumers](/consumers)\n - [Patients](/patients)\n - [Industry](/industry)\n - [Health Professionals](/health-professionals)\n - [Federal, State and Local Officials](/federal-state-local-tribal-and-territorial-officials)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Home](/)\n - [Drugs](/drugs)\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n - What's New Related to Drugs\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n\n\n\n [In this section](#section-nav)\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n - [Meetings, Conferences, & Workshops | Drugs](/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs)\n - [Q&A with FDA Podcast](/drugs/news-events-human-drugs/qa-fda-podcast)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [CDER Conversations](/drugs/news-events-human-drugs/cder-conversations)\n - [From Our Perspective](/drugs/news-events-human-drugs/our-perspective)\n - [Spotlight on CDER Science](/drugs/news-events-human-drugs/spotlight-cder-science)\n - [Things to Know About...](/drugs/news-events-human-drugs/things-know-about)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n# What's New Related to Drugs\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n - [Meetings, Conferences, & Workshops](/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs)\n - [Q&A with FDA Podcast](/drugs/news-events-human-drugs/qa-fda-podcast)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [CDER Conversations](/drugs/news-events-human-drugs/cder-conversations)\n - [From Our Perspective](/drugs/news-events-human-drugs/our-perspective)\n - [Spotlight on CDER Science](/drugs/news-events-human-drugs/spotlight-cder-science)\n - [Things to Know About...](/drugs/news-events-human-drugs/things-know-about)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[RSS Feed for This Page](http://www.fda.gov/AboutFDA/ContactFDA/StayInformed/RSSFeeds/Drugs/rss.xml)\n\n\n\n## Updated Monday through Friday\n\n- [Current and Resolved Drug Shortages and Discontinuations Reported to FDA](https://www.accessdata.fda.gov/scripts/drugshortages/)\n- [Drug Firm Annual Registration Status](https://www.accessdata.fda.gov/scripts/cder/drls/)\n- [Drug Firm Annual Registration Status Download File](/drugs/drug-approvals-and-databases/drug-establishments-current-registration-site-decrs)\n- [National Drug Code Directory](/drugs/drug-approvals-and-databases/national-drug-code-directory)\n- [NDC Unfinished Drugs Excluded Database File](https://www.accessdata.fda.gov/cder/NDC_unfinished_excluded.zip)\n- [NDC Database Excluded Packages and Products](https://www.accessdata.fda.gov/cder/ndc_excluded.zip)\n- [Wholesale Distributor and Third-Party Logistics Providers Reporting](https://www.accessdata.fda.gov/scripts/cder/wdd3plreporting)\n- [Drugs@FDA Data Files](/drugs/drug-approvals-and-databases/drugsfda-data-files)\n\n## Updated Biweekly\n\n- [Competitive Generic Therapy Approvals](/drugs/generic-drugs/competitive-generic-therapy-approvals)\n\n\n\n\n\n**September 11, 2026**\n\n- [FDA Approves First Therapy to Target Muscle Loss in Spinal Muscular Atrophy](/drugs/news-events-human-drugs/fda-approves-first-therapy-target-muscle-loss-spinal-muscular-atrophy)\n- Orange Book\n - [Approved Drug Products with Therapeutic Equivalence Evaluations](/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book)\n - [Orange Book Current Cumulative Supplement](/media/72973/download?attachment) (updated)\n - [Additions/Deletions for Prescription and OTC Drug Product Lists](/drugs/drug-approvals-and-databases/additionsdeletions-prescription-and-otc-drug-product-lists) (updated)\n - [Orange Book Data Files (compressed)](/media/76860/download?attachment) (updated)\n - [Reference Listed Drugs by ANDA Reference Standard List](/media/103879/download?attachment) (updated)\n - [Orange Book Patent Listing Dispute List](/drugs/drug-approvals-and-databases/orange-book-patent-listing-dispute-list) (updated)\n\n- [FDA approves first treatment for children aged 4-11 years with APDS, a rare genetic disorder of the immune system](/drugs/news-events-human-drugs/fda-approves-first-treatment-children-aged-4-11-years-apds-rare-genetic-disorder-immune-system)\n\n**September 9, 2026**\n\n- [FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer](/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-locally-advanced-or-metastatic-non-squamous-non-small)\n\n**September 4, 2026**\n\n- [FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer](/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative)\n- Final Guidance: [Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates](/regulatory-information/search-fda-guidance-documents/temporary-policies-compounding-certain-starter-parenteral-nutrition-drug-products-neonates)\n- Public Notification: [ZUBB Dietary Supplement may be harmful due to hidden ingredient](/drugs/medication-health-fraud-notifications/zubb-dietary-supplement-may-be-harmful-due-hidden-ingredient)\n\n**September 3, 2026**\n\n- Press Release: [FDA Approves First Drug to Treat Alexander Disease](/news-events/press-announcements/fda-approves-first-drug-treat-alexander-disease)\n- CDER Statement: [FDA Update on Estradiol Transdermal Patch Availability](/drugs/drug-alerts-and-statements/fda-update-estradiol-transdermal-patch-availability)\n\n**September 2, 2026**\n\n- Public Notification: [MAXMAN Coffee may be harmful due to hidden drug ingredients](/drugs/medication-health-fraud-notifications/maxman-coffee-may-be-harmful-due-hidden-drug-ingredients)\n\n**September 1, 2026**\n\n- Drug Safety Communication: [FDA Adds Boxed Warning to Labeling for Ferric Carboxymaltose Injection (Injectafer) to Describe Risk of Low Phosphate Levels](/drugs/drug-safety-communications/fda-adds-boxed-warning-labeling-ferric-carboxymaltose-injection-injectafer-describe-risk-low)\n- Draft Guidance: [Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling](/regulatory-information/search-fda-guidance-documents/pharmacokinetics-patients-impaired-hepatic-function-study-design-data-analysis-and-impact-dosing-and)\n\n**August 31, 2026**\n\n- CDER Statement: [International Collaboration to Advance New Testing Methods That Reduce Reliance on Horseshoe Crab Blood](/drugs/drug-alerts-and-statements/international-collaboration-advance-new-testing-methods-reduce-reliance-horseshoe-crab-blood)\n- [FDA Approves Treatment for Essential Thrombocythemia](/drugs/news-events-human-drugs/fda-approves-treatment-essential-thrombocythemia)\n\n**August 28, 2026**\n\n- [FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder](/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder)\n- [FDA Approves Stelara for Pediatric Ulcerative Colitis](/drugs/news-events-human-drugs/fda-approves-stelara-pediatric-ulcerative-colitis)\n\n**August 27, 2026**\n\n- [FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults](/news-events/press-announcements/fda-approves-first-oral-drug-indicated-treat-dermatomyositis-adults)\n- [FDA reminds compounders not to use dietary supplement grade glutathione for injectables](/drugs/human-drug-compounding/fda-reminds-compounders-not-use-dietary-supplement-grade-glutathione-injectables)\n\n**August 25, 2026**\n\n- [FDA Approves Drug to Treat HIV Infection in Newborns](/drugs/news-events-human-drugs/fda-approves-drug-treat-hiv-infection-newborns)\n- Public Notification: [Qu Feng Huo Lou Dan may be harmful due to hidden ingredient](/drugs/medication-health-fraud-notifications/qu-feng-huo-lou-dan-may-be-harmful-due-hidden-ingredient)\n- [FDA Approves First Drug for Warm Autoimmune Hemolytic Anemia](/drugs/news-events-human-drugs/fda-approves-first-drug-warm-autoimmune-hemolytic-anemia)\n\n**August 24, 2026**\n\n- October 14 Webinar: [Navigating the FDA Bayesian Draft Guidance: Design, Analysis, and Review Considerations](/drugs/news-events-human-drugs/navigating-fda-bayesian-draft-guidance-design-analysis-and-review-considerations-10142026)\n\n**August 21, 2026**\n\n- CDER Statement: [FDA Publishes New Product-Specific Guidances to Facilitate Generic Drug Development](/drugs/drug-alerts-and-statements/fda-publishes-new-product-specific-guidances-facilitate-generic-drug-development)\n- Final Guidance: [Evaluation of Therapeutic Equivalence](/regulatory-information/search-fda-guidance-documents/evaluation-therapeutic-equivalence)\n\n**August 18, 2026**\n\n- Public Notifications:\n - [Esbelta Chupapanza Flat Belly may be harmful due to hidden ingredient](/drugs/medication-health-fraud-notifications/esbelta-chupapanza-flat-belly-may-be-harmful-due-hidden-ingredient)\n - [Esbelta Intense Loss may be harmful due to hidden ingredients](/drugs/medication-health-fraud-notifications/esbelta-intense-loss-may-be-harmful-due-hidden-ingredients)\n\n**August 17, 2026**\n\n- Draft Guidance: [Determining Whether to Submit an ANDA or a 505(b)(2) Application](/regulatory-information/search-fda-guidance-documents/determining-whether-submit-anda-or-505b2-application-0)\n\n**August 14, 2026**\n\n- September 9 Public Meeting: [Addressing the Public Health Effects of Opioid Medications](/drugs/news-events-human-drugs/addressing-public-health-effects-opioid-medications-09092026)\n- Orange Book\n - [Approved Drug Products with Therapeutic Equivalence Evaluations](/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book)\n - [Orange Book Current Cumulative Supplement](/media/72973/download?attachment) (updated)\n - [Additions/Deletions for Prescription and OTC Drug Product Lists](/drugs/drug-approvals-and-databases/additionsdeletions-prescription-and-otc-drug-product-lists) (updated)\n - [Orange Book Data Files (compressed)](/media/76860/download?attachment) (updated)\n - [Reference Listed Drugs by ANDA Reference Standard List](/media/103879/download?attachment) (updated)\n - [Orange Book Patent Listing Dispute List](/drugs/drug-approvals-and-databases/orange-book-patent-listing-dispute-list) (updated)\n\n**August 13, 2026**\n\n- [FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma](/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-iberdomide-daratumumab-and-hyaluronidase-fihj-and-dexamethasone)\n- Draft Guidance: [Container Closure Systems for Human Drugs and Biological Products](/regulatory-information/search-fda-guidance-documents/container-closure-systems-human-drugs-and-biological-products)\n- [September 16, 2026 Public Meeting on the Recommendations for Reauthorization of the Prescription Drug User Fee Act (PDUFA)](/drugs/news-events-human-drugs/public-meeting-recommendations-reauthorization-prescription-drug-user-fee-act-pdufa-09162026)\n\n**August 12, 2026**\n\n- Public Notifications:\n - [B. MAGI may be harmful due to hidden ingredients](/drugs/medication-health-fraud-notifications/b-magi-may-be-harmful-due-hidden-ingredients)\n - [DMagic Plus may be harmful due to hidden ingredients](/drugs/medication-health-fraud-notifications/dmagic-plus-may-be-harmful-due-hidden-ingredients)\n - [Premium OrgaZEN 10000 may be harmful due to hidden ingredient](/drugs/medication-health-fraud-notifications/premium-orgazen-10000-may-be-harmful-due-hidden-ingredient)\n - [Anaconda Premium 500K may be harmful due to hidden ingredient](/drugs/medication-health-fraud-notifications/anaconda-premium-500k-may-be-harmful-due-hidden-ingredient)\n\n**August 10, 2026**\n\n- [Public Meeting on the Reauthorization of Generic Drug User Fee Amendments (GDUFA)](/drugs/news-events-human-drugs/public-meeting-reauthorization-generic-drug-user-fee-amendments-gdufa-09172026)\n\n**August 6, 2026**\n\n- [FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma](/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-vusolimogene-oderparepvec-wtpg-combination-nivolumab-melanoma)\n- September 23 Webinar: [Communicating Drug Interaction and QTc Information in the U.S. Prescribing Information](/drugs/news-events-human-drugs/communicating-drug-interaction-and-qtc-information-us-prescribing-information-09232026)\n\n**July 31, 2026**\n\n- [FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer](/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-androgen-receptor-pathway-inhibitor-therapy)\n- September 10 Workshop: [Advancing Generic Drug Development: Modernizing Bioequivalence Approaches for Topical & Transdermal Products](/drugs/news-events-human-drugs/advancing-generic-drug-development-modernizing-bioequivalence-approaches-topical-transdermal)\n- Draft Guidance: [Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs](/regulatory-information/search-fda-guidance-documents/assessing-irritation-and-sensitization-potential-transdermal-and-topical-delivery-systems-andas)\n- Final Guidance: [Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs](/regulatory-information/search-fda-guidance-documents/assessing-adhesion-transdermal-and-topical-delivery-systems-andas)\n- Draft Guidance: [Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts](/regulatory-information/search-fda-guidance-documents/biosimilar-and-interchangeable-biosimilar-products-considerations-container-closure-systems-and)\n\n**July 29, 2026**\n\n- [Drug Trials Snapshots: DECNUPAZ](/drugs/drug-trials-snapshots/drug-trials-snapshots-decnupaz)\n\n**July 28, 2026**\n\n- [FDA Publishes Revised Draft Product-Specific Guidances for Certain Generic Peptide Products](/drugs/drug-alerts-and-statements/fda-publishes-revised-draft-product-specific-guidances-certain-generic-peptide-products)\n\n**July 24, 2026**\n\n- [FDA approves zidesamtinib for *ROS1*-positive non-small cell lung cancer](/drugs/resources-information-approved-drugs/fda-approves-zidesamtinib-ros1-positive-non-small-cell-lung-cancer)\n- Notable Approval: [FDA Approves First Nonprescription Fixed-Dose Combination of Acetaminophen and Naproxen Sodium for 12-Hour Pain Relie](/drugs/news-events-human-drugs/fda-approves-first-nonprescription-fixed-dose-combination-acetaminophen-and-naproxen-sodium-12-hour)f\n\n**July 23, 2026**\n\n- Public Notification: [Kangaroo Intense Venus 3000 may be harmful due to hidden drug ingredient](/drugs/medication-health-fraud-notifications/kangaroo-intense-venus-3000-may-be-harmful-due-hidden-drug-ingredient)\n- September 23-24 Workshop: [FDA/Center for Research on Complex Generics (CRCG) Workshop on Navigating the GLP-1 Generic Drug Pathway](/drugs/news-events-human-drugs/fdacenter-research-complex-generics-crcg-workshop-navigating-glp-1-generic-drug-pathway-09232026)\n\n\n\n\n\n\n\n\n -\n\n\n\n## Content current as of:\n\n\n\n09/11/2026\n\n\n\n\n -\n\n\n\n## Regulated Product(s)\n\n\n - Drugs\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Feedback\n\n\n\n\n\n\n\n\n\n\n\nSUBSCRIBE\n\n Get regular FDA email updates delivered on this topic to your inbox.\n\n\n\n Enter your email address to subscribe:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [FDA Archive](/about-fda/about-website/fdagov-archive)\n - [About FDA](/about-fda)\n - [Accessibility](/about-fda/about-website/internet-accessibility)\n\n\n\n\n\n\n - [Visitor Information](/about-fda/visitor-information)\n - [Website Policies / Privacy](/about-fda/about-website/website-policies)\n - [No FEAR Act](/about-fda/jobs-and-training-fda/no-fear-act)\n - [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n\n\n\n\n\n - [FOIA](/regulatory-information/freedom-information)\n - [HHS.gov](https://www.hhs.gov/)\n - [USA.gov](https://www.usa.gov/)\n\n\n\n\n\n\n\n\n\n\n\n [Contact FDA](/about-fda/contact-fda) [Follow FDA on Facebook](https://www.facebook.com/FDA) [Follow FDA on X](https://x.com/FDA) [Follow FDA on Instagram](https://instagram.com/FDA)\n [Follow FDA on LinkedIn](https://www.linkedin.com/company/fda/) [View FDA videos on YouTube](https://youtube.com/@US_FDA) [Subscribe to FDA RSS feeds](/about-fda/contact-fda/subscribe-podcasts-and-news-feeds)\n\n [](/)\n\n Contact Number 1-888-INFO-FDA (1-888-463-6332)\n\n\n\n\n\n Back to Top",
"content_length": 19314,
"content_type": "text/html",
"description": "Want to know what's new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.",
"status_code": 200,
"success": true,
"title": "What's New Related to Drugs | FDA",
"url": "https://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs"
},
"error": "",
"elapsed": 0.044990946
}{
"tool_name": "web_fetch",
"tool_input": {
"brief": "Isembyld apitegromab details: sponsor, date, label limitations",
"url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-therapy-target-muscle-loss-spinal-muscular-atrophy"
},
"dispatch_id": "toolu_bdrk_01DLfWb143dNACXEFd29PvAn",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_fetch"
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_bdrk_01DLfWb143dNACXEFd29PvAn",
"status": "running",
"result": null,
"error": "",
"elapsed": null,
"fields": {
"progress": {
"message": "Isembyld apitegromab details: sponsor, date, label limitations",
"metadata": {
"browser_chain": false,
"url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-therapy-target-muscle-loss-spinal-muscular-atrophy"
}
},
"status": "running",
"updatedAt": 1789169327323
}
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_bdrk_01DLfWb143dNACXEFd29PvAn",
"status": "completed",
"result": {
"content": "FDA Approves First Therapy to Target Muscle Loss in Spinal Muscular Atrophy | FDA\n\n\n - [Skip to main content](#main-content)\n - [Skip to FDA Search](#search-form)\n - [Skip to in this section menu](#section-nav)\n - [Skip to footer links](#footer)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n  An official website of the United States government Here’s how you know\n\n\n\n\n\n \n\n\n\n**The .gov means it’s official.**\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.\n\n\n\n\n\n\n\n \n\n\n\n**The site is secure.**\n The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n [](/)\n\n\n\n\n - Search\n - Menu\n\n\n\n\n\n\n\n Search FDA Submit search\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Featured\n\n\n - [Report a Product Problem](https://contact.fda.gov/report-problem?utm_medium=%5BREDACTED%5D&utm_source=%5BREDACTED%5D)\n - [Contact FDA](/about-fda/contact-fda)\n - [FDA Guidance Documents](/regulatory-information/search-fda-guidance-documents)\n - [Recalls, Market Withdrawals and Safety Alerts](/safety/recalls-market-withdrawals-safety-alerts)\n - [Press Announcements](/news-events/newsroom/press-announcements)\n - [Warning Letters](/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\n - [Advisory Committees](/advisory-committees)\n - [En Español](/fda-en-espanol)\n\n\n\n\n\n\n\n\n\n\n\n## Products\n\n\n - [Food](/food)\n - [Drugs](/drugs)\n - [Medical Devices](/medical-devices)\n - [Radiation-Emitting Products](/radiation-emitting-products)\n - [Vaccines, Blood, and Biologics](/vaccines-blood-biologics)\n - [Animal and Veterinary](/animal-veterinary)\n - [Cosmetics](/cosmetics)\n - [Tobacco Products](/tobacco-products)\n\n\n\n\n\n\n\n## Topics\n\n\n - [About FDA](/about-fda)\n - [Combination Products](/combination-products)\n - [Regulatory Information](/regulatory-information)\n - [Safety](/safety)\n - [Emergency Preparedness](/emergency-preparedness-and-response)\n - [International Programs](/international-programs)\n - [News and Events](/news-events)\n - [Training and Continuing Education](/training-and-continuing-education)\n - [Inspections and Compliance](/inspections-compliance-enforcement-and-criminal-investigations)\n - [Science and Research](/science-research)\n\n\n\n\n\n\n\n## Information For\n\n\n - [Consumers](/consumers)\n - [Patients](/patients)\n - [Industry](/industry)\n - [Health Professionals](/health-professionals)\n - [Federal, State and Local Officials](/federal-state-local-tribal-and-territorial-officials)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Home](/)\n - [Drugs](/drugs)\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n - FDA Approves First Therapy to Target Muscle Loss in Spinal Muscular Atrophy\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n\n\n\n [In this section](#section-nav)\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n - [Meetings, Conferences, & Workshops | Drugs](/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs)\n - [Q&A with FDA Podcast](/drugs/news-events-human-drugs/qa-fda-podcast)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [CDER Conversations](/drugs/news-events-human-drugs/cder-conversations)\n - [From Our Perspective](/drugs/news-events-human-drugs/our-perspective)\n - [Spotlight on CDER Science](/drugs/news-events-human-drugs/spotlight-cder-science)\n - [Things to Know About...](/drugs/news-events-human-drugs/things-know-about)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n# FDA Approves First Therapy to Target Muscle Loss in Spinal Muscular Atrophy\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n - [Meetings, Conferences, & Workshops](/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs)\n - [Q&A with FDA Podcast](/drugs/news-events-human-drugs/qa-fda-podcast)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [CDER Conversations](/drugs/news-events-human-drugs/cder-conversations)\n - [From Our Perspective](/drugs/news-events-human-drugs/our-perspective)\n - [Spotlight on CDER Science](/drugs/news-events-human-drugs/spotlight-cder-science)\n - [Things to Know About...](/drugs/news-events-human-drugs/things-know-about)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Action\n\nThe U.S. Food and Drug Administration today approved Isembyld (apitegromab-mstn) injection to treat spinal muscular atrophy (SMA) in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment. Isembyld is the first therapy approved for SMA that directly targets muscle loss, working alongside existing treatments to address a critical dimension of the disease.\n\n## Disease or Condition\n\nSMA is a rare, progressive neuromuscular disease affecting approximately 1 in 10,000 live births and is among the leading genetic causes of infant mortality. It is caused by a faulty SMN1 gene that fails to produce a protein essential for motor neuron survival, leading to progressive muscle weakness and wasting.\n\nA backup gene, SMN2, typically produces a broken version of this protein, and existing SMN2-targeted therapies work by correcting this defect so the body can produce enough of the missing protein to keep motor neurons alive. While these treatments have significantly improved outcomes for many patients, those with more advanced disease continue to experience substantial motor limitations (including the ability to walk or move independently), highlighting the need for therapies that directly address muscle loss.\n\n## Effectiveness\n\nThe effectiveness and safety of Isembyld were evaluated in a 52-week randomized, double-blind, placebo-controlled trial ([NCT05156320](https://clinicaltrials.gov/study/NCT05156320)). The trial enrolled 188 participants with SMA between age 2 to 21 years who were not able to move or walk independently. All participants were already receiving an approved SMN2-targeted treatment. Patients were randomly assigned to receive Isembyld 10 mg/kg, Isembyld 20 mg/kg via intravenous infusion, or placebo once every four weeks for approximately one year. The primary analysis was conducted in 156 patients aged 2 to 12 years.\n\nThe study measured change from baseline in the Hammersmith Functional Motor Scale Expanded, a standardized assessment of motor ability. Among patients aged 2 to 12 years, those receiving Isembyld 10 mg/kg showed a significant difference from those on placebo, with treated patients demonstrating improvement in motor function at one year while those on placebo declined. Those in the treatment arm were more than twice as likely than patients in the placebo arm to demonstrate a clinically meaningful improvement (34.2% vs. 13.5%).\n\n## Safety Information\n\nThe most common adverse reactions were upper respiratory tract infections, vomiting, cough, other viral infections, headache, gastroenteritis, and pharyngitis (sore throat). An increased risk of fractures, including serious fractures, was observed in patients treated with Isembyld. Isembyld may cause fetal harm and may affect reproductive function.\n\n## Designation\n\nIsembyld was given [Fast Track](/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track), [Orphan Drug](/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products) and [Rare Pediatric Disease](/industry/medical-products-rare-diseases-and-conditions/rare-pediatric-disease-designation-and-priority-review-voucher-programs) designations. The approval of Isembyld was granted to Scholar Rock, Inc.\n\n\n\n\n\n\n\n\n -\n\n\n\n## Content current as of:\n\n\n\n09/11/2026\n\n\n\n\n -\n\n\n\n## Regulated Product(s)\n\n\n - Drugs\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Feedback\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [FDA Archive](/about-fda/about-website/fdagov-archive)\n - [About FDA](/about-fda)\n - [Accessibility](/about-fda/about-website/internet-accessibility)\n\n\n\n\n\n\n - [Visitor Information](/about-fda/visitor-information)\n - [Website Policies / Privacy](/about-fda/about-website/website-policies)\n - [No FEAR Act](/about-fda/jobs-and-training-fda/no-fear-act)\n - [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n\n\n\n\n\n - [FOIA](/regulatory-information/freedom-information)\n - [HHS.gov](https://www.hhs.gov/)\n - [USA.gov](https://www.usa.gov/)\n\n\n\n\n\n\n\n\n\n\n\n [Contact FDA](/about-fda/contact-fda) [Follow FDA on Facebook](https://www.facebook.com/FDA) [Follow FDA on X](https://x.com/FDA) [Follow FDA on Instagram](https://instagram.com/FDA)\n [Follow FDA on LinkedIn](https://www.linkedin.com/company/fda/) [View FDA videos on YouTube](https://youtube.com/@US_FDA) [Subscribe to FDA RSS feeds](/about-fda/contact-fda/subscribe-podcasts-and-news-feeds)\n\n [](/)\n\n Contact Number 1-888-INFO-FDA (1-888-463-6332)\n\n\n\n\n\n Back to Top",
"content_length": 9160,
"content_type": "text/html",
"description": "The U.S. Food and Drug Administration today approved Isembyld (apitegromab-mstn) injection to treat spinal muscular atrophy (SMA) in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment. Isembyld is the first therapy approved for SMA that dire",
"status_code": 200,
"success": true,
"title": "FDA Approves First Therapy to Target Muscle Loss in Spinal Muscular Atrophy | FDA",
"url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-therapy-target-muscle-loss-spinal-muscular-atrophy"
},
"error": "",
"elapsed": 0.072182784
}{
"tool_name": "web_fetch",
"tool_input": {
"brief": "Sevabertinib approval details",
"url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-locally-advanced-or-metastatic-non-squamous-non-small"
},
"dispatch_id": "toolu_bdrk_01C9K8zpTGjqhMmAu8Kqke8u",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_fetch"
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_bdrk_01C9K8zpTGjqhMmAu8Kqke8u",
"status": "running",
"result": null,
"error": "",
"elapsed": null,
"fields": {
"progress": {
"message": "Sevabertinib approval details",
"metadata": {
"browser_chain": false,
"url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-locally-advanced-or-metastatic-non-squamous-non-small"
}
},
"status": "running",
"updatedAt": 1789169327342
}
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_bdrk_01C9K8zpTGjqhMmAu8Kqke8u",
"status": "completed",
"result": {
"content": "FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer | FDA\n\n\n - [Skip to main content](#main-content)\n - [Skip to FDA Search](#search-form)\n - [Skip to in this section menu](#section-nav)\n - [Skip to footer links](#footer)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n  An official website of the United States government Here’s how you know\n\n\n\n\n\n \n\n\n\n**The .gov means it’s official.**\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.\n\n\n\n\n\n\n\n \n\n\n\n**The site is secure.**\n The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n [](/)\n\n\n\n\n - Search\n - Menu\n\n\n\n\n\n\n\n Search FDA Submit search\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Featured\n\n\n - [Report a Product Problem](https://contact.fda.gov/report-problem?utm_medium=%5BREDACTED%5D&utm_source=%5BREDACTED%5D)\n - [Contact FDA](/about-fda/contact-fda)\n - [FDA Guidance Documents](/regulatory-information/search-fda-guidance-documents)\n - [Recalls, Market Withdrawals and Safety Alerts](/safety/recalls-market-withdrawals-safety-alerts)\n - [Press Announcements](/news-events/newsroom/press-announcements)\n - [Warning Letters](/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\n - [Advisory Committees](/advisory-committees)\n - [En Español](/fda-en-espanol)\n\n\n\n\n\n\n\n\n\n\n\n## Products\n\n\n - [Food](/food)\n - [Drugs](/drugs)\n - [Medical Devices](/medical-devices)\n - [Radiation-Emitting Products](/radiation-emitting-products)\n - [Vaccines, Blood, and Biologics](/vaccines-blood-biologics)\n - [Animal and Veterinary](/animal-veterinary)\n - [Cosmetics](/cosmetics)\n - [Tobacco Products](/tobacco-products)\n\n\n\n\n\n\n\n## Topics\n\n\n - [About FDA](/about-fda)\n - [Combination Products](/combination-products)\n - [Regulatory Information](/regulatory-information)\n - [Safety](/safety)\n - [Emergency Preparedness](/emergency-preparedness-and-response)\n - [International Programs](/international-programs)\n - [News and Events](/news-events)\n - [Training and Continuing Education](/training-and-continuing-education)\n - [Inspections and Compliance](/inspections-compliance-enforcement-and-criminal-investigations)\n - [Science and Research](/science-research)\n\n\n\n\n\n\n\n## Information For\n\n\n - [Consumers](/consumers)\n - [Patients](/patients)\n - [Industry](/industry)\n - [Health Professionals](/health-professionals)\n - [Federal, State and Local Officials](/federal-state-local-tribal-and-territorial-officials)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Home](/)\n - [Drugs](/drugs)\n - [Development & Approval Process | Drugs](/drugs/development-approval-process-drugs)\n - [Drug Approvals and Databases](/drugs/development-approval-process-drugs/drug-approvals-and-databases)\n - [Resources for Information | Approved Drugs](/drugs/drug-approvals-and-databases/resources-information-approved-drugs)\n - FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer\n\n\n - [Resources for Information | Approved Drugs](/drugs/drug-approvals-and-databases/resources-information-approved-drugs)\n\n\n\n\n\n\n\n [In this section](#section-nav)\n\n\n - [Resources for Information | Approved Drugs](/drugs/drug-approvals-and-databases/resources-information-approved-drugs)\n\n\n\n\n - [Oncology (Cancer)/Hematologic Malignancies Approval Notifications](/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications)\n - [Ongoing | Cancer Accelerated Approvals](/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals)\n - [Verified Clinical Benefit | Cancer Accelerated Approvals](/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals)\n - [Withdrawn | Cancer Accelerated Approvals](/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals)\n - [Other | Cancer Accelerated Approvals](/drugs/resources-information-approved-drugs/other-cancer-accelerated-approvals)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n# FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Resources for Information | Approved Drugs](/drugs/drug-approvals-and-databases/resources-information-approved-drugs)\n\n\n\n\n - [Oncology (Cancer)/Hematologic Malignancies Approval Notifications](/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications)\n - [Ongoing | Cancer Accelerated Approvals](/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals)\n - [Verified Clinical Benefit | Cancer Accelerated Approvals](/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals)\n - [Withdrawn | Cancer Accelerated Approvals](/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals)\n - [Other | Cancer Accelerated Approvals](/drugs/resources-information-approved-drugs/other-cancer-accelerated-approvals)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nOn September 9, 2026, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.\n\nThis approval expands the existing indication for sevabertinib, which was previously granted accelerated approval for adult patients with locally advanced or metastatic non-squamous NSCLC with HER2 (ERBB2) TKD activating mutations who had received prior systemic therapy.\n\nFull prescribing information for Hyrnuo will be posted on [Drugs@FDA](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm).\n\n## Efficacy and Safety\n\nEfficacy was evaluated in patients with locally advanced or metastatic, non-squamous NSCLC with HER2 (ERBB2) TKD activating mutations who received sevabertinib in SOHO-01 (NCT05099172), an open-label, single-arm, multicenter, multi-cohort clinical trial. HER2 (ERBB2) activating mutations were determined in tumor tissue or plasma by local laboratories prior to enrollment.\n\nThe major efficacy outcome measures were confirmed objective response rate (ORR) and duration of response (DOR) as assessed by blinded independent central review (BICR) using RECIST v1.1. Among 69 patients with locally advanced or metastatic NSCLC with HER2 (ERBB2) TKD activating mutations who had not received prior systemic therapy, the ORR was 75% (95% CI: 64, 85); 73% of responding patients had a DOR of ≥6 months and 38% had a DOR of ≥12 months.\n\nThe prescribing information includes warnings and precautions for diarrhea, hepatotoxicity, interstitial lung disease (ILD)/pneumonitis, left ventricular dysfunction, ocular toxicity, pancreatic enzyme elevation, and embryo-fetal toxicity.\n\n## Recommended Dosage\n\nThe recommended sevabertinib dose is 20 mg orally twice daily with food, until disease progression or unacceptable toxicity.\n\nThis review was conducted under [Project Orbis](/about-fda/oncology-center-excellence/project-orbis), an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA). The application reviews are ongoing at the other regulatory agencies.\n\nThis review used the [Assessment Aid](/about-fda/oncology-center-excellence/assessment-aid), a voluntary submission from the applicant to facilitate the FDA’s assessment.\n\nThis application was granted priority review. Sevabertinib received breakthrough therapy designation and orphan drug designation. A description of FDA expedited programs is in the [Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics](/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-and-biologics).\n\nHealthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s [MedWatch Reporting System](https://www.accessdata.fda.gov/scripts/medwatch/index.cfm) or by calling 1-800-FDA-1088.\n\nFor assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s [Project Facilitate](/about-fda/oncology-center-excellence/project-facilitate) at 240-402-0004 or email [OncProjectFacilitate@fda.hhs.gov](mailto:OncProjectFacilitate@fda.hhs.gov).\n\n\n\n\n\n\n\n\n -\n\n\n\n## Content current as of:\n\n\n\n09/09/2026\n\n\n\n\n -\n\n\n\n## Regulated Product(s)\n\n\n - Drugs\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Feedback\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [FDA Archive](/about-fda/about-website/fdagov-archive)\n - [About FDA](/about-fda)\n - [Accessibility](/about-fda/about-website/internet-accessibility)\n\n\n\n\n\n\n - [Visitor Information](/about-fda/visitor-information)\n - [Website Policies / Privacy](/about-fda/about-website/website-policies)\n - [No FEAR Act](/about-fda/jobs-and-training-fda/no-fear-act)\n - [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n\n\n\n\n\n - [FOIA](/regulatory-information/freedom-information)\n - [HHS.gov](https://www.hhs.gov/)\n - [USA.gov](https://www.usa.gov/)\n\n\n\n\n\n\n\n\n\n\n\n [Contact FDA](/about-fda/contact-fda) [Follow FDA on Facebook](https://www.facebook.com/FDA) [Follow FDA on X](https://x.com/FDA) [Follow FDA on Instagram](https://instagram.com/FDA)\n [Follow FDA on LinkedIn](https://www.linkedin.com/company/fda/) [View FDA videos on YouTube](https://youtube.com/@US_FDA) [Subscribe to FDA RSS feeds](/about-fda/contact-fda/subscribe-podcasts-and-news-feeds)\n\n [](/)\n\n Contact Number 1-888-INFO-FDA (1-888-463-6332)\n\n\n\n\n\n Back to Top",
"content_length": 10445,
"content_type": "text/html",
"description": "On September 9, 2026, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB",
"status_code": 200,
"success": true,
"title": "FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer | FDA",
"url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-locally-advanced-or-metastatic-non-squamous-non-small"
},
"error": "",
"elapsed": 0.072531109
}{
"tool_name": "web_fetch",
"tool_input": {
"brief": "Camizestrant approval details",
"url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative"
},
"dispatch_id": "toolu_bdrk_01S2gAMvY65qmuF1F11tYXyX",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_fetch"
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_bdrk_01S2gAMvY65qmuF1F11tYXyX",
"status": "running",
"result": null,
"error": "",
"elapsed": null,
"fields": {
"progress": {
"message": "Camizestrant approval details",
"metadata": {
"browser_chain": false,
"url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative"
}
},
"status": "running",
"updatedAt": 1789169327325
}
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_bdrk_01S2gAMvY65qmuF1F11tYXyX",
"status": "completed",
"result": {
"content": "FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer | FDA\n\n\n - [Skip to main content](#main-content)\n - [Skip to FDA Search](#search-form)\n - [Skip to in this section menu](#section-nav)\n - [Skip to footer links](#footer)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n  An official website of the United States government Here’s how you know\n\n\n\n\n\n \n\n\n\n**The .gov means it’s official.**\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.\n\n\n\n\n\n\n\n \n\n\n\n**The site is secure.**\n The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n [](/)\n\n\n\n\n - Search\n - Menu\n\n\n\n\n\n\n\n Search FDA Submit search\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Featured\n\n\n - [Report a Product Problem](https://contact.fda.gov/report-problem?utm_medium=%5BREDACTED%5D&utm_source=%5BREDACTED%5D)\n - [Contact FDA](/about-fda/contact-fda)\n - [FDA Guidance Documents](/regulatory-information/search-fda-guidance-documents)\n - [Recalls, Market Withdrawals and Safety Alerts](/safety/recalls-market-withdrawals-safety-alerts)\n - [Press Announcements](/news-events/newsroom/press-announcements)\n - [Warning Letters](/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\n - [Advisory Committees](/advisory-committees)\n - [En Español](/fda-en-espanol)\n\n\n\n\n\n\n\n\n\n\n\n## Products\n\n\n - [Food](/food)\n - [Drugs](/drugs)\n - [Medical Devices](/medical-devices)\n - [Radiation-Emitting Products](/radiation-emitting-products)\n - [Vaccines, Blood, and Biologics](/vaccines-blood-biologics)\n - [Animal and Veterinary](/animal-veterinary)\n - [Cosmetics](/cosmetics)\n - [Tobacco Products](/tobacco-products)\n\n\n\n\n\n\n\n## Topics\n\n\n - [About FDA](/about-fda)\n - [Combination Products](/combination-products)\n - [Regulatory Information](/regulatory-information)\n - [Safety](/safety)\n - [Emergency Preparedness](/emergency-preparedness-and-response)\n - [International Programs](/international-programs)\n - [News and Events](/news-events)\n - [Training and Continuing Education](/training-and-continuing-education)\n - [Inspections and Compliance](/inspections-compliance-enforcement-and-criminal-investigations)\n - [Science and Research](/science-research)\n\n\n\n\n\n\n\n## Information For\n\n\n - [Consumers](/consumers)\n - [Patients](/patients)\n - [Industry](/industry)\n - [Health Professionals](/health-professionals)\n - [Federal, State and Local Officials](/federal-state-local-tribal-and-territorial-officials)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Home](/)\n - [Drugs](/drugs)\n - [Development & Approval Process | Drugs](/drugs/development-approval-process-drugs)\n - [Drug Approvals and Databases](/drugs/development-approval-process-drugs/drug-approvals-and-databases)\n - [Resources for Information | Approved Drugs](/drugs/drug-approvals-and-databases/resources-information-approved-drugs)\n - FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer\n\n\n - [Resources for Information | Approved Drugs](/drugs/drug-approvals-and-databases/resources-information-approved-drugs)\n\n\n\n\n\n\n\n [In this section](#section-nav)\n\n\n - [Resources for Information | Approved Drugs](/drugs/drug-approvals-and-databases/resources-information-approved-drugs)\n\n\n\n\n - [Oncology (Cancer)/Hematologic Malignancies Approval Notifications](/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications)\n - [Ongoing | Cancer Accelerated Approvals](/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals)\n - [Verified Clinical Benefit | Cancer Accelerated Approvals](/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals)\n - [Withdrawn | Cancer Accelerated Approvals](/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals)\n - [Other | Cancer Accelerated Approvals](/drugs/resources-information-approved-drugs/other-cancer-accelerated-approvals)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n# FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Resources for Information | Approved Drugs](/drugs/drug-approvals-and-databases/resources-information-approved-drugs)\n\n\n\n\n - [Oncology (Cancer)/Hematologic Malignancies Approval Notifications](/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications)\n - [Ongoing | Cancer Accelerated Approvals](/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals)\n - [Verified Clinical Benefit | Cancer Accelerated Approvals](/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals)\n - [Withdrawn | Cancer Accelerated Approvals](/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals)\n - [Other | Cancer Accelerated Approvals](/drugs/resources-information-approved-drugs/other-cancer-accelerated-approvals)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nOn September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (*ESR1)* mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.\n\nFDA also approved the Guardant360 CDx assay as a companion diagnostic device to identify patients with breast cancer with *ESR1* mutations for treatment with camizestrant.\n\nFull prescribing information for Etcamah will be posted on [Drugs@FDA](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm).\n\n## Efficacy and Safety\n\nEfficacy was evaluated in SERENA-6 (NCT04964934), a randomized, double-blind, placebo-controlled, multicenter trial to assess switching to camizestrant in combination with a CDK4/6 inhibitor versus continuing an aromatase inhibitor (AI) in combination with a CDK4/6 inhibitor in adult patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer with detectable *ESR1* mutations. The *ESR1* mutation status was assessed by blood circulating tumor deoxyribonucleic acid (ctDNA) testing using the Guardant360 CDx assay during first-line treatment with an AI and a CDK4/6 inhibitor. All patients were required to be currently receiving treatment of an AI in combination with a CDK4/6 inhibitor for ≥ 6 months as the initial endocrine based treatment with no evidence of disease progression as per investigator assessment. A total of 315 patients were randomized (1:1) to receive either camizestrant once daily in combination with a CDK4/6 inhibitor or AI (anastrozole or letrozole) orally once daily in combination with a CDK4/6 inhibitor.\n\nThe primary efficacy outcome measure was investigator-assessed progression-free survival (PFS) per RECIST v1.1. An additional efficacy outcome measure included overall survival (OS). Median PFS was 16 months (95% CI: 12.7, 18.2) in the camizestrant and CDK4/6 inhibitor arm and 9.2 months (95% CI: 7.2, 9.5) in the AI and CDK4/6 inhibitor arm (Hazard ratio 0.44 [95% CI: 0.31, 0.60]; p-value < 0.00001). At the time of the PFS analysis, OS data were not mature.\n\nThe prescribing information includes a boxed warning for the risk of arrhythmia due to QTc interval prolongation when concomitantly used with QTc interval prolonging drugs, as well as warnings and precautions for bradycardia and embryo-fetal toxicity.\n\n## Recommended Dosage\n\nThe recommended camizestrant dose is 75 mg orally once daily, with or without food, until disease progression or unacceptable toxicity. Administer camizestrant in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib). Continue the CDK4/6 inhibitor at the same dosage as when the *ESR1* mutation was detected. Refer to the prescribing information of the CDK4/6 inhibitor for additional dosing information.\n\nCamizestrant in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) is being granted accelerated approval based on PFS measured from detection of *ESR1* mutation. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). For more information on ongoing accelerated approvals in oncology, refer to [Project Confirm](/about-fda/oncology-center-excellence/project-confirm).\n\nThis review was conducted under [Project Orbis](/about-fda/oncology-center-excellence/project-orbis), an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration (TGA), the Brazilian Health Regulatory Agency (ANVISA), Health Canada, Singapore’s Health Sciences Authority (HSA), and Switzerland’s Swissmedic. The application reviews may be ongoing at the other regulatory agencies.\n\nThis application was discussed at an [Oncology Drugs Advisory Committee meeting](/advisory-committees/human-drug-advisory-committees/oncologic-drugs-advisory-committee). This review used the [Assessment Aid](/about-fda/oncology-center-excellence/assessment-aid), a voluntary submission from the applicant to facilitate the FDA’s assessment.\n\nThis application was granted standard review. Camizestrant received breakthrough therapy designation. A description of FDA expedited programs is in the [Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics](/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-and-biologics).\n\nHealthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s [MedWatch Reporting System](https://www.accessdata.fda.gov/scripts/medwatch/index.cfm) or by calling 1-800-FDA-1088.\n\nFor assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s [Project Facilitate](/about-fda/oncology-center-excellence/project-facilitate) at 240-402-0004 or email [OncProjectFacilitate@fda.hhs.gov](mailto:OncProjectFacilitate@fda.hhs.gov).\n\n\n\n\n\n\n\n\n -\n\n\n\n## Content current as of:\n\n\n\n09/04/2026\n\n\n\n\n -\n\n\n\n## Regulated Product(s)\n\n\n - Drugs\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Feedback\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [FDA Archive](/about-fda/about-website/fdagov-archive)\n - [About FDA](/about-fda)\n - [Accessibility](/about-fda/about-website/internet-accessibility)\n\n\n\n\n\n\n - [Visitor Information](/about-fda/visitor-information)\n - [Website Policies / Privacy](/about-fda/about-website/website-policies)\n - [No FEAR Act](/about-fda/jobs-and-training-fda/no-fear-act)\n - [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n\n\n\n\n\n - [FOIA](/regulatory-information/freedom-information)\n - [HHS.gov](https://www.hhs.gov/)\n - [USA.gov](https://www.usa.gov/)\n\n\n\n\n\n\n\n\n\n\n\n [Contact FDA](/about-fda/contact-fda) [Follow FDA on Facebook](https://www.facebook.com/FDA) [Follow FDA on X](https://x.com/FDA) [Follow FDA on Instagram](https://instagram.com/FDA)\n [Follow FDA on LinkedIn](https://www.linkedin.com/company/fda/) [View FDA videos on YouTube](https://youtube.com/@US_FDA) [Subscribe to FDA RSS feeds](/about-fda/contact-fda/subscribe-podcasts-and-news-feeds)\n\n [](/)\n\n Contact Number 1-888-INFO-FDA (1-888-463-6332)\n\n\n\n\n\n Back to Top",
"content_length": 12351,
"content_type": "text/html",
"description": "On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults....",
"status_code": 200,
"success": true,
"title": "FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer | FDA",
"url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative"
},
"error": "",
"elapsed": 0.066324114
}{
"tool_name": "web_fetch",
"tool_input": {
"brief": "Alexander disease drug approval details",
"url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-alexander-disease"
},
"dispatch_id": "toolu_bdrk_01MjmuRaNNtLzgoZJs4YU5LM",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_fetch"
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_bdrk_01MjmuRaNNtLzgoZJs4YU5LM",
"status": "running",
"result": null,
"error": "",
"elapsed": null,
"fields": {
"progress": {
"message": "Alexander disease drug approval details",
"metadata": {
"browser_chain": false,
"url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-alexander-disease"
}
},
"status": "running",
"updatedAt": 1789169327328
}
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_bdrk_01MjmuRaNNtLzgoZJs4YU5LM",
"status": "completed",
"result": {
"content": "FDA Approves First Drug to Treat Alexander Disease | FDA\n\n\n - [Skip to main content](#main-content)\n - [Skip to FDA Search](#search-form)\n - [Skip to in this section menu](#section-nav)\n - [Skip to footer links](#footer)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n  An official website of the United States government Here’s how you know\n\n\n\n\n\n \n\n\n\n**The .gov means it’s official.**\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.\n\n\n\n\n\n\n\n \n\n\n\n**The site is secure.**\n The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n [](/)\n\n\n\n\n - Search\n - Menu\n\n\n\n\n\n\n\n Search FDA Submit search\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Featured\n\n\n - [Report a Product Problem](https://contact.fda.gov/report-problem?utm_medium=%5BREDACTED%5D&utm_source=%5BREDACTED%5D)\n - [Contact FDA](/about-fda/contact-fda)\n - [FDA Guidance Documents](/regulatory-information/search-fda-guidance-documents)\n - [Recalls, Market Withdrawals and Safety Alerts](/safety/recalls-market-withdrawals-safety-alerts)\n - [Press Announcements](/news-events/newsroom/press-announcements)\n - [Warning Letters](/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\n - [Advisory Committees](/advisory-committees)\n - [En Español](/fda-en-espanol)\n\n\n\n\n\n\n\n\n\n\n\n## Products\n\n\n - [Food](/food)\n - [Drugs](/drugs)\n - [Medical Devices](/medical-devices)\n - [Radiation-Emitting Products](/radiation-emitting-products)\n - [Vaccines, Blood, and Biologics](/vaccines-blood-biologics)\n - [Animal and Veterinary](/animal-veterinary)\n - [Cosmetics](/cosmetics)\n - [Tobacco Products](/tobacco-products)\n\n\n\n\n\n\n\n## Topics\n\n\n - [About FDA](/about-fda)\n - [Combination Products](/combination-products)\n - [Regulatory Information](/regulatory-information)\n - [Safety](/safety)\n - [Emergency Preparedness](/emergency-preparedness-and-response)\n - [International Programs](/international-programs)\n - [News and Events](/news-events)\n - [Training and Continuing Education](/training-and-continuing-education)\n - [Inspections and Compliance](/inspections-compliance-enforcement-and-criminal-investigations)\n - [Science and Research](/science-research)\n\n\n\n\n\n\n\n## Information For\n\n\n - [Consumers](/consumers)\n - [Patients](/patients)\n - [Industry](/industry)\n - [Health Professionals](/health-professionals)\n - [Federal, State and Local Officials](/federal-state-local-tribal-and-territorial-officials)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Home](/)\n - [News & Events](/news-events)\n - [FDA Newsroom](/news-events/fda-newsroom)\n - [Press Announcements](/news-events/fda-newsroom/press-announcements)\n - FDA Approves First Drug to Treat Alexander Disease\n\n\n - [Press Announcements](/news-events/fda-newsroom/press-announcements)\n\n\n\n\n\n\n\n [In this section](#section-nav)\n\n\n - [Press Announcements](/news-events/fda-newsroom/press-announcements)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFDA News Release\n\n\n\n# FDA Approves First Drug to Treat Alexander Disease\n\n\n\nNew therapy is the first to directly target the underlying cause of this rare neurological disease\n\n\n\n\n\n\n\n\n\n\n\n\n\n[** More Press Announcements](/news-events/newsroom/press-announcements)\n\n\n\n\n -\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n For Immediate Release: September 03, 2026\n\n\n\n\n\n\n\nThe U.S. Food and Drug Administration has approved Zanvastro (zilganersen) injection for the treatment of Alexander disease in pediatric and adult patients. Zanvastro is the first FDA-approved treatment for Alexander disease and the first therapy to directly target the protein buildup that drives the disease.\n\n“For patients with Alexander disease and their families, there have been no approved treatment options — only supportive care while the disease progresses,” **said Emily Freilich, M.D., Director of the Division of Neurology I in the FDA’s Center for Drug Evaluation and Research**. “Today’s approval is a landmark moment for this community, offering the first therapy that addresses the underlying cause of this rare and serious disease.”\n\nAlexander disease is a rare, progressive neurological disorder caused by mutations in the gene that produces glial fibrillary acidic protein (GFAP). When this protein is abnormal, it accumulates in the brain’s supportive cells, causing damage to the nervous system over time. The disease affects less than 1 in a million people and can cause a wide range of serious and potentially life-threatening problems, including seizures, loss of developmental milestones, difficulty walking, muscle weakness, and increased pressure in the brain.\n\nZanvastro is an antisense oligonucleotide — a type of medicine that works by reducing the production of the abnormal GFAP protein before it can accumulate and cause further damage. It is administered as an injection into the spinal canal every three months by a trained healthcare professional.\n\nThe efficacy and safety of Zanvastro were evaluated in a multicenter, randomized, controlled clinical study ([NCT04849741](https://clinicaltrials.gov/study/NCT04849741?term=%5BREDACTED%5D&viewType=%5BREDACTED%5D&rank=%5BREDACTED%5D)) enrolling 49 pediatric and adult patients with Alexander disease 2 years of age and older, and in an open-label substudy of 4 patients less than 2 years of age. Because Alexander disease is so rare and can affect patients across a wide range of ages, the FDA evaluated the available evidence in support of an indication covering patients from infancy through adulthood.\n\nIn patients aged 5 years and older who had measurable difficulties with walking at baseline, those treated with Zanvastro showed significantly better walking speed at 61 weeks compared to those who received no treatment. In children aged 2 to 4 years, where walking speed is not a reliable measure of progress, a broader assessment of motor skills — including standing, walking, running, and jumping — was used instead. Children treated with Zanvastro showed improvement on this measure while those in the control group declined.\n\nFor patients under 2 years of age, direct clinical trial data were limited by the rarity of the disease and lack of concurrent control. Pharmacokinetic modeling confirmed that drug levels in this age group are expected to be similar to those seen in older children at the same dose. This observation was also supported by safety data from four patients under 2 years of age treated in the study, as well as the safety data observed in the older pediatric patients. This approach supported extending the indication to the youngest patients while maintaining the evidentiary standards required to support approval.\n\nThe most common side effects of Zanvastro are vomiting, back pain, cough, headache, and post-lumbar puncture syndrome. Patients and caregivers should inform their healthcare provider if symptoms consistent with meningitis develop, as aseptic meningitis has been reported in patients treated with Zanvastro. Patients and providers should carefully review the full prescribing information when making treatment decisions.\n\nZanvastro received [Orphan Drug](/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products), [Fast Track](/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track), [Breakthrough Therapy](/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy), and [Rare Pediatric Disease and Priority Review Voucher](/industry/medical-products-rare-diseases-and-conditions/rare-pediatric-disease-designation-and-priority-review-voucher-programs) designations, reflecting the serious and rare nature of Alexander disease, and FDA’s commitment to rare disease drug development.\n\nThe approval of Zanvastro for the treatment of Alexander disease was granted to Ionis Pharmaceuticals, Inc.\n\n---\n\n\n\n**Media:**\n[FDA Request for Comment](https://www.hhs.gov/request-for-comment-form/index.html?Agency=%5BREDACTED%5D)\n202-690-6343\n\n\n\n\n\n\n\n**Consumer:**\n888-INFO-FDA\n\n\n\n\n\n\n\n\n\n###\n\n\n\n\n\n\n\nBoilerplate\n\n\n\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.\n\n\n\n\n\n\n\n---\n\n\n\n\n\n\n\n\n\n -\n\n\n\n## Content current as of:\n\n\n\n09/03/2026\n\n\n\n\n -\n\n\n\n## Regulated Product(s)\n\n\n - Drugs\n\n\n\n\n -\n\n\n\n## Follow FDA\n\n\n - [Follow @US_FDA on X](https://x.com/FDA)\n - [Follow FDA on Facebook](https://www.facebook.com/FDA)\n - [Follow @FDAMedia on X](https://x.com/FDAMedia)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Feedback\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [FDA Archive](/about-fda/about-website/fdagov-archive)\n - [About FDA](/about-fda)\n - [Accessibility](/about-fda/about-website/internet-accessibility)\n\n\n\n\n\n\n - [Visitor Information](/about-fda/visitor-information)\n - [Website Policies / Privacy](/about-fda/about-website/website-policies)\n - [No FEAR Act](/about-fda/jobs-and-training-fda/no-fear-act)\n - [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n\n\n\n\n\n - [FOIA](/regulatory-information/freedom-information)\n - [HHS.gov](https://www.hhs.gov/)\n - [USA.gov](https://www.usa.gov/)\n\n\n\n\n\n\n\n\n\n\n\n [Contact FDA](/about-fda/contact-fda) [Follow FDA on Facebook](https://www.facebook.com/FDA) [Follow FDA on X](https://x.com/FDA) [Follow FDA on Instagram](https://instagram.com/FDA)\n [Follow FDA on LinkedIn](https://www.linkedin.com/company/fda/) [View FDA videos on YouTube](https://youtube.com/@US_FDA) [Subscribe to FDA RSS feeds](/about-fda/contact-fda/subscribe-podcasts-and-news-feeds)\n\n [](/)\n\n Contact Number 1-888-INFO-FDA (1-888-463-6332)\n\n\n\n\n\n Back to Top",
"content_length": 10383,
"content_type": "text/html",
"description": "The U.S. Food and Drug Administration has approved Zanvastro (zilganersen) injection for the treatment of Alexander disease in pediatric and adult patients.",
"status_code": 200,
"success": true,
"title": "FDA Approves First Drug to Treat Alexander Disease | FDA",
"url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-alexander-disease"
},
"error": "",
"elapsed": 0.066973473
}{
"tool_name": "web_fetch",
"tool_input": {
"brief": "Polycythemia vera drug approval details",
"url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder"
},
"dispatch_id": "toolu_bdrk_01XtK5NRwzvRQUHejP2bpF7B",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_fetch"
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_bdrk_01XtK5NRwzvRQUHejP2bpF7B",
"status": "running",
"result": null,
"error": "",
"elapsed": null,
"fields": {
"progress": {
"message": "Polycythemia vera drug approval details",
"metadata": {
"browser_chain": false,
"url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder"
}
},
"status": "running",
"updatedAt": 1789169327331
}
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_bdrk_01XtK5NRwzvRQUHejP2bpF7B",
"status": "completed",
"result": {
"content": "FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder | FDA\n\n\n - [Skip to main content](#main-content)\n - [Skip to FDA Search](#search-form)\n - [Skip to in this section menu](#section-nav)\n - [Skip to footer links](#footer)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n  An official website of the United States government Here’s how you know\n\n\n\n\n\n \n\n\n\n**The .gov means it’s official.**\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.\n\n\n\n\n\n\n\n \n\n\n\n**The site is secure.**\n The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n [](/)\n\n\n\n\n - Search\n - Menu\n\n\n\n\n\n\n\n Search FDA Submit search\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Featured\n\n\n - [Report a Product Problem](https://contact.fda.gov/report-problem?utm_medium=%5BREDACTED%5D&utm_source=%5BREDACTED%5D)\n - [Contact FDA](/about-fda/contact-fda)\n - [FDA Guidance Documents](/regulatory-information/search-fda-guidance-documents)\n - [Recalls, Market Withdrawals and Safety Alerts](/safety/recalls-market-withdrawals-safety-alerts)\n - [Press Announcements](/news-events/newsroom/press-announcements)\n - [Warning Letters](/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\n - [Advisory Committees](/advisory-committees)\n - [En Español](/fda-en-espanol)\n\n\n\n\n\n\n\n\n\n\n\n## Products\n\n\n - [Food](/food)\n - [Drugs](/drugs)\n - [Medical Devices](/medical-devices)\n - [Radiation-Emitting Products](/radiation-emitting-products)\n - [Vaccines, Blood, and Biologics](/vaccines-blood-biologics)\n - [Animal and Veterinary](/animal-veterinary)\n - [Cosmetics](/cosmetics)\n - [Tobacco Products](/tobacco-products)\n\n\n\n\n\n\n\n## Topics\n\n\n - [About FDA](/about-fda)\n - [Combination Products](/combination-products)\n - [Regulatory Information](/regulatory-information)\n - [Safety](/safety)\n - [Emergency Preparedness](/emergency-preparedness-and-response)\n - [International Programs](/international-programs)\n - [News and Events](/news-events)\n - [Training and Continuing Education](/training-and-continuing-education)\n - [Inspections and Compliance](/inspections-compliance-enforcement-and-criminal-investigations)\n - [Science and Research](/science-research)\n\n\n\n\n\n\n\n## Information For\n\n\n - [Consumers](/consumers)\n - [Patients](/patients)\n - [Industry](/industry)\n - [Health Professionals](/health-professionals)\n - [Federal, State and Local Officials](/federal-state-local-tribal-and-territorial-officials)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Home](/)\n - [News & Events](/news-events)\n - [FDA Newsroom](/news-events/fda-newsroom)\n - [Press Announcements](/news-events/fda-newsroom/press-announcements)\n - FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder\n\n\n - [Press Announcements](/news-events/fda-newsroom/press-announcements)\n\n\n\n\n\n\n\n [In this section](#section-nav)\n\n\n - [Press Announcements](/news-events/fda-newsroom/press-announcements)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFDA News Release\n\n\n\n# FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder\n\n\n\nFirst-in-class therapy targets the biology driving red blood cell overproduction in polycythemia vera\n\n\n\n\n\n\n\n\n\n\n\n\n\n[** More Press Announcements](/news-events/newsroom/press-announcements)\n\n\n\n\n -\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n For Immediate Release: August 28, 2026\n\n\n\n\n\n\n\nThe U.S. Food and Drug Administration today approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder that causes the body to make too many red blood cells. The excess cells can thicken the blood and increase the risk of cardiovascular issues, such as blood clots, stroke and heart attack.\n\nMimrylo offers a new treatment approach for patients whose disease has not been adequately controlled with existing therapies. It is the first approved treatment for polycythemia vera that mimics hepcidin, a hormone that naturally regulates iron in the body. By limiting the iron available to make new red blood cells, Mimrylo helps reduce their overproduction and keep red blood cell levels under control. This novel approach offers a new option for patients who have not achieved adequate control with existing therapies.\n\n“People living with polycythemia vera have long faced the challenge of managing a chronic blood disorder with frequent blood draws to help address the consequences of the red blood cell overproduction,” **said Tanya Wroblewski, M.D., Director of the Division of Nonmalignant Hematology within the FDA’s Center for Drug Evaluation and Research**. “Today's approval of Mimrylo offers a new, first-in-class option that has the potential to meaningfully reduce patient burden.\"\n\nA key goal of treatment for polycythemia vera is keeping the proportion of red blood cells in the blood (hematocrit) below 45% to reduce cardiovascular risks. This often requires phlebotomy, a procedure that removes blood from a vein to lower the number of red blood cells in the body. However, some patients continue to need frequent phlebotomies despite treatment, creating an ongoing burden.\n\nThe safety and efficacy of Mimrylo were evaluated in the [VERIFY](https://clinicaltrials.gov/study/NCT05210790?id=%5BREDACTED%5D&viewType=%5BREDACTED%5D&rank=%5BREDACTED%5D) trial, a multicenter, randomized, double-blind, placebo-controlled phase 3 study of 293 adults with polycythemia vera who required frequent phlebotomies despite ongoing standard-of-care therapy. Patients were randomized 1:1 to receive either Mimrylo or placebo over 32 weeks. Mimrylo treatment started at 19 mg, administered subcutaneously (under the skin) once weekly, and was titrated to maintain hematocrit levels below 45%.\n\nEfficacy was measured by the proportion of patients who did not meet criteria for phlebotomy between weeks 20 and 32 of the study. Overall, 76.9% of patients on Mimrylo required no phlebotomies during the 32-week period compared to 32.9% on placebo. The most common adverse reactions were injection site reactions and anemia.\n\nMimrylo received [priority review](/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review). The approval was granted to Takeda Pharmaceuticals America, Inc.\n\n\n\n###\n\n\n\n\n\n\n\nBoilerplate\n\n\n\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.\n\n\n\n\n\n\n\n---\n\n\n\n\n\n\n\n\n\n -\n\n\n\n## Content current as of:\n\n\n\n08/28/2026\n\n\n\n\n -\n\n\n\n## Regulated Product(s)\n\n\n - Drugs\n\n\n\n\n -\n\n\n\n## Follow FDA\n\n\n - [Follow @US_FDA on X](https://x.com/FDA)\n - [Follow FDA on Facebook](https://www.facebook.com/FDA)\n - [Follow @FDAMedia on X](https://x.com/FDAMedia)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Feedback\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [FDA Archive](/about-fda/about-website/fdagov-archive)\n - [About FDA](/about-fda)\n - [Accessibility](/about-fda/about-website/internet-accessibility)\n\n\n\n\n\n\n - [Visitor Information](/about-fda/visitor-information)\n - [Website Policies / Privacy](/about-fda/about-website/website-policies)\n - [No FEAR Act](/about-fda/jobs-and-training-fda/no-fear-act)\n - [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n\n\n\n\n\n - [FOIA](/regulatory-information/freedom-information)\n - [HHS.gov](https://www.hhs.gov/)\n - [USA.gov](https://www.usa.gov/)\n\n\n\n\n\n\n\n\n\n\n\n [Contact FDA](/about-fda/contact-fda) [Follow FDA on Facebook](https://www.facebook.com/FDA) [Follow FDA on X](https://x.com/FDA) [Follow FDA on Instagram](https://instagram.com/FDA)\n [Follow FDA on LinkedIn](https://www.linkedin.com/company/fda/) [View FDA videos on YouTube](https://youtube.com/@US_FDA) [Subscribe to FDA RSS feeds](/about-fda/contact-fda/subscribe-podcasts-and-news-feeds)\n\n [](/)\n\n Contact Number 1-888-INFO-FDA (1-888-463-6332)\n\n\n\n\n\n Back to Top",
"content_length": 8591,
"content_type": "text/html",
"description": "The U.S. Food and Drug Administration today approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder that causes the body to make too many red blood cells.",
"status_code": 200,
"success": true,
"title": "FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder | FDA",
"url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder"
},
"error": "",
"elapsed": 0.08078912
}{
"tool_name": "web_fetch",
"tool_input": {
"brief": "Besremi essential thrombocythemia details",
"url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-essential-thrombocythemia"
},
"dispatch_id": "toolu_bdrk_01ViftE3khEH41sPJysoTEZU",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_fetch"
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_bdrk_01ViftE3khEH41sPJysoTEZU",
"status": "running",
"result": null,
"error": "",
"elapsed": null,
"fields": {
"progress": {
"message": "Besremi essential thrombocythemia details",
"metadata": {
"browser_chain": false,
"url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-essential-thrombocythemia"
}
},
"status": "running",
"updatedAt": 1789169327334
}
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_bdrk_01ViftE3khEH41sPJysoTEZU",
"status": "completed",
"result": {
"content": "FDA Approves Treatment for Essential Thrombocythemia | FDA\n\n\n - [Skip to main content](#main-content)\n - [Skip to FDA Search](#search-form)\n - [Skip to in this section menu](#section-nav)\n - [Skip to footer links](#footer)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n  An official website of the United States government Here’s how you know\n\n\n\n\n\n \n\n\n\n**The .gov means it’s official.**\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.\n\n\n\n\n\n\n\n \n\n\n\n**The site is secure.**\n The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n [](/)\n\n\n\n\n - Search\n - Menu\n\n\n\n\n\n\n\n Search FDA Submit search\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Featured\n\n\n - [Report a Product Problem](https://contact.fda.gov/report-problem?utm_medium=%5BREDACTED%5D&utm_source=%5BREDACTED%5D)\n - [Contact FDA](/about-fda/contact-fda)\n - [FDA Guidance Documents](/regulatory-information/search-fda-guidance-documents)\n - [Recalls, Market Withdrawals and Safety Alerts](/safety/recalls-market-withdrawals-safety-alerts)\n - [Press Announcements](/news-events/newsroom/press-announcements)\n - [Warning Letters](/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\n - [Advisory Committees](/advisory-committees)\n - [En Español](/fda-en-espanol)\n\n\n\n\n\n\n\n\n\n\n\n## Products\n\n\n - [Food](/food)\n - [Drugs](/drugs)\n - [Medical Devices](/medical-devices)\n - [Radiation-Emitting Products](/radiation-emitting-products)\n - [Vaccines, Blood, and Biologics](/vaccines-blood-biologics)\n - [Animal and Veterinary](/animal-veterinary)\n - [Cosmetics](/cosmetics)\n - [Tobacco Products](/tobacco-products)\n\n\n\n\n\n\n\n## Topics\n\n\n - [About FDA](/about-fda)\n - [Combination Products](/combination-products)\n - [Regulatory Information](/regulatory-information)\n - [Safety](/safety)\n - [Emergency Preparedness](/emergency-preparedness-and-response)\n - [International Programs](/international-programs)\n - [News and Events](/news-events)\n - [Training and Continuing Education](/training-and-continuing-education)\n - [Inspections and Compliance](/inspections-compliance-enforcement-and-criminal-investigations)\n - [Science and Research](/science-research)\n\n\n\n\n\n\n\n## Information For\n\n\n - [Consumers](/consumers)\n - [Patients](/patients)\n - [Industry](/industry)\n - [Health Professionals](/health-professionals)\n - [Federal, State and Local Officials](/federal-state-local-tribal-and-territorial-officials)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Home](/)\n - [Drugs](/drugs)\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n - FDA Approves Treatment for Essential Thrombocythemia\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n\n\n\n [In this section](#section-nav)\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n - [Meetings, Conferences, & Workshops | Drugs](/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs)\n - [Q&A with FDA Podcast](/drugs/news-events-human-drugs/qa-fda-podcast)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [CDER Conversations](/drugs/news-events-human-drugs/cder-conversations)\n - [From Our Perspective](/drugs/news-events-human-drugs/our-perspective)\n - [Spotlight on CDER Science](/drugs/news-events-human-drugs/spotlight-cder-science)\n - [Things to Know About...](/drugs/news-events-human-drugs/things-know-about)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n# FDA Approves Treatment for Essential Thrombocythemia\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n - [Meetings, Conferences, & Workshops](/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs)\n - [Q&A with FDA Podcast](/drugs/news-events-human-drugs/qa-fda-podcast)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [CDER Conversations](/drugs/news-events-human-drugs/cder-conversations)\n - [From Our Perspective](/drugs/news-events-human-drugs/our-perspective)\n - [Spotlight on CDER Science](/drugs/news-events-human-drugs/spotlight-cder-science)\n - [Things to Know About...](/drugs/news-events-human-drugs/things-know-about)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Action\n\nThe U.S. Food and Drug Administration has approved Besremi (ropeginterferon alfa-2b-njft) injection for the treatment of adults with essential thrombocythemia.\n\nThe recommended starting dosage of Besremi is 250 mcg by subcutaneous (under the skin) injection. The dosage should be increased to 350 mcg at 2 weeks and then to the maintenance dosage of 500 mcg at 4 weeks. The maintenance dose should be given every 2 weeks unless a dose modification is required due to tolerability.\n\n## Disease or Condition\n\nEssential thrombocythemia is a rare blood disorder that causes the bone marrow to make too many platelets, which can increase the risk for blood clots and bleeding when the platelet count is very high. Platelets are small cell fragments in blood that help form clots to stop or prevent bleeding.\n\n## Effectiveness\n\nThe effectiveness of Besremi was evaluated in the [SURPASS ET study](https://clinicaltrials.gov/study/NCT04285086?cond=%5BREDACTED%5D&titles=%5BREDACTED%5D&viewType=%5BREDACTED%5D&rank=%5BREDACTED%5D), an open-label, multicenter, randomized study that compared Besremi to anagrelide for the treatment of essential thrombocythemia. The study enrolled 174 adults with essential thrombocythemia who had an inadequate response or intolerance to hydroxyurea; 91 patients received Besremi and 83 patients received anagrelide (another medicine approved for treating essential thrombocythemia).\n\nBesremi was administered subcutaneously every 2 weeks at the starting dose of 250 mcg (Week 0), then 350 mcg (Week 2), and 500 mcg (Week 4), and then remained fixed at 500 mcg every two weeks for the remainder of the study. Anagrelide was administered orally according to its product label and treatment practices. Patients in both arms also received low-dose aspirin (75 to 150 mg/day per local practice), unless contraindicated.\n\nEfficacy was evaluated in the SURPASS ET study by assessing durable Modified European Leukemia Net (ELN) response rates at Months 9 and 12. Patients were considered responders if they met all of the following criteria: blood count remission, improvement or non-progression of splenomegaly (enlarged spleen), and absence of bleeding or clotting events. Treatment with Besremi demonstrated a higher response rate of 37.4% compared to a response rate of 3.6% for the anagrelide treatment group at both Months 9 and 12.\n\n## Safety Information\n\nThe most common adverse reactions included transaminase elevations (high levels of liver enzymes), anemia, fever, bacterial infection, pruritus (itching), and weight loss. See the full prescribing information for all risks associated with Besremi.\n\n\n\n\n\n\n\n\n -\n\n\n\n## Content current as of:\n\n\n\n08/31/2026\n\n\n\n\n -\n\n\n\n## Regulated Product(s)\n\n\n - Drugs\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Feedback\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [FDA Archive](/about-fda/about-website/fdagov-archive)\n - [About FDA](/about-fda)\n - [Accessibility](/about-fda/about-website/internet-accessibility)\n\n\n\n\n\n\n - [Visitor Information](/about-fda/visitor-information)\n - [Website Policies / Privacy](/about-fda/about-website/website-policies)\n - [No FEAR Act](/about-fda/jobs-and-training-fda/no-fear-act)\n - [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n\n\n\n\n\n - [FOIA](/regulatory-information/freedom-information)\n - [HHS.gov](https://www.hhs.gov/)\n - [USA.gov](https://www.usa.gov/)\n\n\n\n\n\n\n\n\n\n\n\n [Contact FDA](/about-fda/contact-fda) [Follow FDA on Facebook](https://www.facebook.com/FDA) [Follow FDA on X](https://x.com/FDA) [Follow FDA on Instagram](https://instagram.com/FDA)\n [Follow FDA on LinkedIn](https://www.linkedin.com/company/fda/) [View FDA videos on YouTube](https://youtube.com/@US_FDA) [Subscribe to FDA RSS feeds](/about-fda/contact-fda/subscribe-podcasts-and-news-feeds)\n\n [](/)\n\n Contact Number 1-888-INFO-FDA (1-888-463-6332)\n\n\n\n\n\n Back to Top",
"content_length": 8397,
"content_type": "text/html",
"description": "The U.S. Food and Drug Administration has approved Besremi (ropeginterferon alfa-2b-njft) injection for the treatment of adults with essential thrombocythemia.",
"status_code": 200,
"success": true,
"title": "FDA Approves Treatment for Essential Thrombocythemia | FDA",
"url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-essential-thrombocythemia"
},
"error": "",
"elapsed": 0.069776391
}{
"tool_name": "web_fetch",
"tool_input": {
"brief": "Joenja pediatric APDS details",
"url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-children-aged-4-11-years-apds-rare-genetic-disorder-immune-system"
},
"dispatch_id": "toolu_bdrk_015MUYSMWLAkbv9qiuELjQys",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_fetch"
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_bdrk_015MUYSMWLAkbv9qiuELjQys",
"status": "running",
"result": null,
"error": "",
"elapsed": null,
"fields": {
"progress": {
"message": "Joenja pediatric APDS details",
"metadata": {
"browser_chain": false,
"url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-children-aged-4-11-years-apds-rare-genetic-disorder-immune-system"
}
},
"status": "running",
"updatedAt": 1789169327336
}
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_bdrk_015MUYSMWLAkbv9qiuELjQys",
"status": "completed",
"result": {
"content": "FDA approves first treatment for children aged 4-11 years with APDS, a rare genetic disorder of the immune system | FDA\n\n\n - [Skip to main content](#main-content)\n - [Skip to FDA Search](#search-form)\n - [Skip to in this section menu](#section-nav)\n - [Skip to footer links](#footer)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n  An official website of the United States government Here’s how you know\n\n\n\n\n\n \n\n\n\n**The .gov means it’s official.**\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.\n\n\n\n\n\n\n\n \n\n\n\n**The site is secure.**\n The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n [](/)\n\n\n\n\n - Search\n - Menu\n\n\n\n\n\n\n\n Search FDA Submit search\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Featured\n\n\n - [Report a Product Problem](https://contact.fda.gov/report-problem?utm_medium=%5BREDACTED%5D&utm_source=%5BREDACTED%5D)\n - [Contact FDA](/about-fda/contact-fda)\n - [FDA Guidance Documents](/regulatory-information/search-fda-guidance-documents)\n - [Recalls, Market Withdrawals and Safety Alerts](/safety/recalls-market-withdrawals-safety-alerts)\n - [Press Announcements](/news-events/newsroom/press-announcements)\n - [Warning Letters](/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\n - [Advisory Committees](/advisory-committees)\n - [En Español](/fda-en-espanol)\n\n\n\n\n\n\n\n\n\n\n\n## Products\n\n\n - [Food](/food)\n - [Drugs](/drugs)\n - [Medical Devices](/medical-devices)\n - [Radiation-Emitting Products](/radiation-emitting-products)\n - [Vaccines, Blood, and Biologics](/vaccines-blood-biologics)\n - [Animal and Veterinary](/animal-veterinary)\n - [Cosmetics](/cosmetics)\n - [Tobacco Products](/tobacco-products)\n\n\n\n\n\n\n\n## Topics\n\n\n - [About FDA](/about-fda)\n - [Combination Products](/combination-products)\n - [Regulatory Information](/regulatory-information)\n - [Safety](/safety)\n - [Emergency Preparedness](/emergency-preparedness-and-response)\n - [International Programs](/international-programs)\n - [News and Events](/news-events)\n - [Training and Continuing Education](/training-and-continuing-education)\n - [Inspections and Compliance](/inspections-compliance-enforcement-and-criminal-investigations)\n - [Science and Research](/science-research)\n\n\n\n\n\n\n\n## Information For\n\n\n - [Consumers](/consumers)\n - [Patients](/patients)\n - [Industry](/industry)\n - [Health Professionals](/health-professionals)\n - [Federal, State and Local Officials](/federal-state-local-tribal-and-territorial-officials)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Home](/)\n - [Drugs](/drugs)\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n - FDA approves first treatment for children aged 4-11 years with APDS, a rare genetic disorder of the immune system\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n\n\n\n [In this section](#section-nav)\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n - [Meetings, Conferences, & Workshops | Drugs](/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs)\n - [Q&A with FDA Podcast](/drugs/news-events-human-drugs/qa-fda-podcast)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [CDER Conversations](/drugs/news-events-human-drugs/cder-conversations)\n - [From Our Perspective](/drugs/news-events-human-drugs/our-perspective)\n - [Spotlight on CDER Science](/drugs/news-events-human-drugs/spotlight-cder-science)\n - [Things to Know About...](/drugs/news-events-human-drugs/things-know-about)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n# FDA approves first treatment for children aged 4-11 years with APDS, a rare genetic disorder of the immune system\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [News & Events for Human Drugs](/drugs/news-events-human-drugs)\n\n\n\n\n - [Meetings, Conferences, & Workshops](/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs)\n - [Q&A with FDA Podcast](/drugs/news-events-human-drugs/qa-fda-podcast)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [CDER Conversations](/drugs/news-events-human-drugs/cder-conversations)\n - [From Our Perspective](/drugs/news-events-human-drugs/our-perspective)\n - [Spotlight on CDER Science](/drugs/news-events-human-drugs/spotlight-cder-science)\n - [Things to Know About...](/drugs/news-events-human-drugs/things-know-about)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Action\n\nFDA has approved Joenja (leniolisib) tablets as the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) in children 4-11 years who weigh at least 27 kg. Joenja was first approved in 2023 for the same indication in patients 12 years and older at a dose of 70 mg orally twice a day. Children 4-11 years take a weight-based dosage (40, 50, or 70 mg) orally twice a day, approximately 12 hours apart.\n\n## Disease or Condition\n\nActivated PI3K delta syndrome (APDS) is a rare genetic disorder that impairs cells of the immune system. These cells are necessary to recognize and attack foreign invaders, such as viruses and bacteria, to prevent infection. People with APDS develop recurrent infections, particularly in the sinuses, ears, and respiratory tract. They also develop enlarged lymph nodes, tonsils, spleen, and other organs that can cause obstruction in the airway and gastrointestinal tract. Individuals with this condition often have low numbers of white blood cells, including red cells and platelets. Patients with APDS are more prone to develop blood cell cancers, like lymphoma.\n\nAPDS is caused by mutations in the PIK3CD or PIK3R1 genes that encode a protein called phosphoinositide-3 kinase delta (PI3K delta), which is important for the normal development and function of white blood cells in the body.\n\n## Effectiveness\n\nFor the original approval for patients 12 years and older with APDS, the efficacy of Joenja was evaluated in the placebo-controlled portion of Study 2201 ([NCT02435173](https://clinicaltrials.gov/study/NCT02435173)). This was a 12‑week blinded, randomized, placebo-controlled study of 31 patients 12 years and older with confirmed APDS-associated genetic PI3K delta mutations, with a documented variant in either PIK3CD or PIK3R1.\n\nDuring the study, 21 patients received 70 mg of Joenja and 10 received placebo twice a day for 12 weeks. The co‑primary efficacy endpoints were improvement in lymphoproliferation (lymph node reduction) and the normalization of immunophenotype as measured by the percentage of naïve B cells out of total B cells.\n\nBy day 85 of the study, patients taking Joenja saw a reduction in lymph node size and a 37 percent improvement in naïve B cells counts compared to placebo, indicating a correction of the underlying immune defect.\n\nFor the approval for patients aged 4-11 years, safety and pharmacokinetic data were established from a single-arm, open-label study ([Study LE 3301](https://clinicaltrials.gov/study/NCT05438407)). In this study, 8 patients received the recommended Joenja dosage based on body weight. The pharmacokinetic data demonstrated no clinically significant difference between patients younger or older than 12 years.\n\n## Safety Information\n\nThe most common side effects of Joenja in children aged 4-11 were stomach pain, respiratory tract infection, diarrhea, headache, cough, nausea, rhinitis, and alopecia. Patients with moderate-to-severe liver impairment should not use Joenja. See full prescribing information for additional information on risks associated with Joenja.\n\n## Designations\n\nJoenja received orphan drug designation, rare pediatric disease designation, and priority review.\n\n\n\n\n\n\n\n\n -\n\n\n\n## Content current as of:\n\n\n\n09/11/2026\n\n\n\n\n -\n\n\n\n## Regulated Product(s)\n\n\n - Drugs\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Feedback\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [FDA Archive](/about-fda/about-website/fdagov-archive)\n - [About FDA](/about-fda)\n - [Accessibility](/about-fda/about-website/internet-accessibility)\n\n\n\n\n\n\n - [Visitor Information](/about-fda/visitor-information)\n - [Website Policies / Privacy](/about-fda/about-website/website-policies)\n - [No FEAR Act](/about-fda/jobs-and-training-fda/no-fear-act)\n - [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n\n\n\n\n\n - [FOIA](/regulatory-information/freedom-information)\n - [HHS.gov](https://www.hhs.gov/)\n - [USA.gov](https://www.usa.gov/)\n\n\n\n\n\n\n\n\n\n\n\n [Contact FDA](/about-fda/contact-fda) [Follow FDA on Facebook](https://www.facebook.com/FDA) [Follow FDA on X](https://x.com/FDA) [Follow FDA on Instagram](https://instagram.com/FDA)\n [Follow FDA on LinkedIn](https://www.linkedin.com/company/fda/) [View FDA videos on YouTube](https://youtube.com/@US_FDA) [Subscribe to FDA RSS feeds](/about-fda/contact-fda/subscribe-podcasts-and-news-feeds)\n\n [](/)\n\n Contact Number 1-888-INFO-FDA (1-888-463-6332)\n\n\n\n\n\n Back to Top",
"content_length": 9169,
"content_type": "text/html",
"description": "FDA has approved Joenja (leniolisib) tablets as the first treatment for activated phosphoinositide 3-kinase delta syndrome in children 4-11 years who weigh at least 27 kg. Joenja was first approved in 2023 for the same indication in patients 12 years and older at a dose of 70 mg orally twice a day.",
"status_code": 200,
"success": true,
"title": "FDA approves first treatment for children aged 4-11 years with APDS, a rare genetic disorder of the immune system | FDA",
"url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-children-aged-4-11-years-apds-rare-genetic-disorder-immune-system"
},
"error": "",
"elapsed": 0.073023815
}{
"tool_name": "web_fetch",
"tool_input": {
"brief": "Novel drug approvals 2026 with dates and sponsors",
"max_age_seconds": 3600,
"url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026"
},
"dispatch_id": "toolu_bdrk_01VbnF1wo8wyXsDQNsr4nkvG",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_fetch"
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_bdrk_01VbnF1wo8wyXsDQNsr4nkvG",
"status": "running",
"result": null,
"error": "",
"elapsed": null,
"fields": {
"progress": {
"message": "Novel drug approvals 2026 with dates and sponsors",
"metadata": {
"browser_chain": false,
"url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026"
}
},
"status": "running",
"updatedAt": 1789169327339
}
}{
"tool_name": "web_fetch",
"dispatch_id": "toolu_bdrk_01VbnF1wo8wyXsDQNsr4nkvG",
"status": "completed",
"result": {
"content": "Novel Drug Approvals for 2026 | FDA\n\n\n - [Skip to main content](#main-content)\n - [Skip to FDA Search](#search-form)\n - [Skip to in this section menu](#section-nav)\n - [Skip to footer links](#footer)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n  An official website of the United States government Here’s how you know\n\n\n\n\n\n \n\n\n\n**The .gov means it’s official.**\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.\n\n\n\n\n\n\n\n \n\n\n\n**The site is secure.**\n The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n [](/)\n\n\n\n\n - Search\n - Menu\n\n\n\n\n\n\n\n Search FDA Submit search\n\n\n\n\n\n\n\n\n\n\n\n\n\n## Featured\n\n\n - [Report a Product Problem](https://contact.fda.gov/report-problem?utm_medium=%5BREDACTED%5D&utm_source=%5BREDACTED%5D)\n - [Contact FDA](/about-fda/contact-fda)\n - [FDA Guidance Documents](/regulatory-information/search-fda-guidance-documents)\n - [Recalls, Market Withdrawals and Safety Alerts](/safety/recalls-market-withdrawals-safety-alerts)\n - [Press Announcements](/news-events/newsroom/press-announcements)\n - [Warning Letters](/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)\n - [Advisory Committees](/advisory-committees)\n - [En Español](/fda-en-espanol)\n\n\n\n\n\n\n\n\n\n\n\n## Products\n\n\n - [Food](/food)\n - [Drugs](/drugs)\n - [Medical Devices](/medical-devices)\n - [Radiation-Emitting Products](/radiation-emitting-products)\n - [Vaccines, Blood, and Biologics](/vaccines-blood-biologics)\n - [Animal and Veterinary](/animal-veterinary)\n - [Cosmetics](/cosmetics)\n - [Tobacco Products](/tobacco-products)\n\n\n\n\n\n\n\n## Topics\n\n\n - [About FDA](/about-fda)\n - [Combination Products](/combination-products)\n - [Regulatory Information](/regulatory-information)\n - [Safety](/safety)\n - [Emergency Preparedness](/emergency-preparedness-and-response)\n - [International Programs](/international-programs)\n - [News and Events](/news-events)\n - [Training and Continuing Education](/training-and-continuing-education)\n - [Inspections and Compliance](/inspections-compliance-enforcement-and-criminal-investigations)\n - [Science and Research](/science-research)\n\n\n\n\n\n\n\n## Information For\n\n\n - [Consumers](/consumers)\n - [Patients](/patients)\n - [Industry](/industry)\n - [Health Professionals](/health-professionals)\n - [Federal, State and Local Officials](/federal-state-local-tribal-and-territorial-officials)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Home](/)\n - [Drugs](/drugs)\n - [Development & Approval Process | Drugs](/drugs/development-approval-process-drugs)\n - [Novel Drug Approvals at FDA](/drugs/development-approval-process-drugs/novel-drug-approvals-fda)\n - Novel Drug Approvals for 2026\n\n\n - [Novel Drug Approvals at FDA](/drugs/development-approval-process-drugs/novel-drug-approvals-fda)\n\n\n\n\n\n\n\n [In this section](#section-nav)\n\n\n - [Novel Drug Approvals at FDA](/drugs/development-approval-process-drugs/novel-drug-approvals-fda)\n\n\n\n\n - [Novel Drug Approvals for 2026](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)\n - [Novel Drug Approvals for 2025](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)\n - [Novel Drug Approvals for 2024](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)\n - [Novel Drug Approvals for 2023](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)\n - [Novel Drug Approvals for 2022](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022)\n - [Novel Drug Approvals for 2021](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n# Novel Drug Approvals for 2026\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [Novel Drug Approvals at FDA](/drugs/development-approval-process-drugs/novel-drug-approvals-fda)\n\n\n\n\n - [Novel Drug Approvals for 2026](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)\n - [Novel Drug Approvals for 2025](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)\n - [Novel Drug Approvals for 2024](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)\n - [Novel Drug Approvals for 2023](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)\n - [Novel Drug Approvals for 2022](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022)\n - [Novel Drug Approvals for 2021](/drugs/novel-drug-approvals-fda/novel-drug-approvals-2021)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n## What are \"Novel\" Drugs?\n\n\"Novel\" drugs are new drugs never before approved or marketed in the U.S. See [Drugs@FDA](https://www.accessdata.fda.gov/scripts/cder/daf/) for information about all of CDER’s approved drugs and biological products.\n\n## FDA Novel Drug Therapy Approvals for 2026\n\n| No. | Drug Name | Active Ingredient | Approval Date | FDA-approved use on approval date* |\n| 39. | Isembyld | apitegromab-mstn | 9/11/2026 | To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment |\n| 38. | Etcamah | camizestrant | 9/4/2026 | To treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy |\n| 37. | Zanvastro | zilganersen | 9/3/2026 | To treat Alexander disease in pediatric and adult patients |\n| 36. | Mimrylo | rusfertide | 8/28/2026 | To treat erythrocytosis in adults with polycythemia vera |\n| 35. | Lisraya | brepocitinib | 8/27/2026 | To treat dermatomyositis in adults |\n| 34. | Rasonque | daraxonrasib | 8/26/2026 | To treat metastatic pancreatic cancer |\n| 33. | Pasatru | garetosmab-grts | 8/19/2026 | To reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva |\n| 32. | Zenbexus | iberdomide | 8/13/2026 | To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent |\n| 31. | Tauklarify | florquinitau F 18 | 8/13/2026 | To be used for positron emission tomography of the brain in adults with cognitive impairment who are being evaluated for Alzheimer disease to identify patients with tau neurofibrillary tangle pathology |\n| 30. | Orzeyful | oveporexton | 8/5/2026 | To treat narcolepsy type 1 |\n| 29. | Simtriyo | centanafadine | 7/24/2026 | To treat attention-deficit hyperactivity disorder |\n| 28. | Lytenava | bevacizumab-vikg | 7/24/2026 | To treat patients with neovascular (wet) age-related macular degeneration |\n| 27. | Jideytro | zidesamtinib | 7/22/2026 | To treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after receiving a ROS1 kinase inhibitor |\n| 26. | Lipfendra | enlicitide decanoate | 7/15/2026 | To reduce low-density lipoprotein cholesterol |\n| 25. | Revtorpyk | gedatolisib | 7/14/2026 | In combination with fulvestran, to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting |\n| 24. | Trutakna | atacicept-vymj | 7/7/2026 | To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression |\n| 23. | Lumvoa | veligrotug-vvze | 6/26/2026 | To treat thyroid eye disease |\n| 22. | Utebzi | tebipenem pivoxil | 6/17/2026 | To treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options |\n| 21. | Ambelvist | gadoquatrane | 6/12/2026 | To detect and visualize lesions with abnormal vascularity, in conjunction with MRI |\n| 20. | Cypsedo | cipepofol | 5/29/2026 | To induce general anesthesia in adults undergoing surgery |\n| 19. | Xocova | ensitrelvir | 5/29/2026 | To use as post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) following contact with an individual who has COVID-19 |\n| 18. | Zaynich | cefepime and zidebactam | 5/29/2026 | To treat complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms |\n| 17. | Decnupaz | pivekimab sunirine-pvzy | 5/27/2026 | To treat adults with blastic plasmacytoid dendritic cell neoplasm\n[Drug Trials Snapshot](/drugs/drug-trials-snapshots/drug-trials-snapshots-decnupaz) |\n| 16. | Hepcludex | bulevirtide-gmod | 5/22/2026 | To treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis |\n| 15. | Baxfendy | baxdrostat | 5/15/2026 | To treat hypertension in combination with other antihypertensive drugs |\n| 14. | Beqalzi | sonrotoclax | 5/13/2026 | To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor |\n| 13. | Veppanu | vepdegestrant | 5/1/2026 | To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy |\n| 12. | Idvynso | doravirine and islatravir | 4/20/2026 | To treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine |\n| 11. | Foundayo | orforglipron | 4/1/2026 | To reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity |\n| 10. | Awiqli | insulin icodec-abae | 3/26/2026 | To improve glycemic control in adults with type 2 diabetes mellitus |\n| 9. | Lifyorli | relacorilant | 3/25/2026 | To treat platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic treatment regimens, at least one of which included bevacizumab |\n| 8. | Avlayah | tividenofusp alfa-eknm | 3/24/2026 | To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II) |\n| 7. | Icotyde | icotrokinra | 3/17/2026 | To treat moderate-to-severe plaque psoriasis in patients 12 years and older who weigh at least 40 kg and who are candidates for systemic therapy or phototherapy \n[Drug Trials Snapshot](/drugs/drug-trials-snapshots/drug-trials-snapshots-icotyde) |\n| 6. | Lynavoy | linerixibat | 3/17/2026 | To treat cholestatic pruritus associated with primary biliary cholangitis |\n| 5. | Yuviwel | navepegritide | 2/27/2026 | To increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses |\n| 4. | Loargys | pegzilarginase-nbln | 2/23/2026 | To treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction |\n| 3. | Bysanti | milsaperidone | 2/20/2026 | To treat schizophrenia and to treat manic or mixed episodes associated with bipolar I disorder |\n| 2. | Adquey | difamilast | 2/12/2026 | To treat mild to moderate atopic dermatitis |\n| 1. | Zycubo | copper histidinate | 1/12/2026 | To treat Menkes disease\n[Drug Trials Snapshot](/drugs/drug-trials-snapshots/drug-trials-snapshots-zycubo) |\n\n---\n\n*The listed “FDA-approved use” on this page is for presentation purposes only. To see the FDA-approved conditions of use [e.g., indication(s), population(s), dosing regimen(s)] for each of these products, please see the most recently approved Prescribing Information (or Label) available at [Drugs@FDA](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm). You can search by drug name, active ingredient, or application number.\n\n\n\n\n\n\n\n\n -\n\n\n\n## Content current as of:\n\n\n\n09/11/2026\n\n\n\n\n -\n\n\n\n## Regulated Product(s)\n\n\n - Drugs\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Feedback\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n - [FDA Archive](/about-fda/about-website/fdagov-archive)\n - [About FDA](/about-fda)\n - [Accessibility](/about-fda/about-website/internet-accessibility)\n\n\n\n\n\n\n - [Visitor Information](/about-fda/visitor-information)\n - [Website Policies / Privacy](/about-fda/about-website/website-policies)\n - [No FEAR Act](/about-fda/jobs-and-training-fda/no-fear-act)\n - [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n\n\n\n\n\n - [FOIA](/regulatory-information/freedom-information)\n - [HHS.gov](https://www.hhs.gov/)\n - [USA.gov](https://www.usa.gov/)\n\n\n\n\n\n\n\n\n\n\n\n [Contact FDA](/about-fda/contact-fda) [Follow FDA on Facebook](https://www.facebook.com/FDA) [Follow FDA on X](https://x.com/FDA) [Follow FDA on Instagram](https://instagram.com/FDA)\n [Follow FDA on LinkedIn](https://www.linkedin.com/company/fda/) [View FDA videos on YouTube](https://youtube.com/@US_FDA) [Subscribe to FDA RSS feeds](/about-fda/contact-fda/subscribe-podcasts-and-news-feeds)\n\n [](/)\n\n Contact Number 1-888-INFO-FDA (1-888-463-6332)\n\n\n\n\n\n Back to Top",
"content_length": 13692,
"content_type": "text/html",
"description": "FDA Novel Drug Therapy Approvals for 2026",
"status_code": 200,
"success": true,
"title": "Novel Drug Approvals for 2026 | FDA",
"url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026"
},
"error": "",
"elapsed": 0.076817406
}{
"tool_name": "web_search",
"tool_input": {
"num": 5,
"q": "Besremi ropeginterferon alfa-2b-njft PharmaEssentia essential thrombocythemia approval August 2026"
},
"dispatch_id": "toolu_bdrk_015puCt6LJALjYstTUUUb5uL",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_search"
}{
"tool_name": "web_search",
"dispatch_id": "toolu_bdrk_015puCt6LJALjYstTUUUb5uL",
"status": "completed",
"result": {
"count": 5,
"query": "Besremi ropeginterferon alfa-2b-njft PharmaEssentia essential thrombocythemia approval August 2026",
"results": [
{
"link": "https://us.pharmaessentia.com/fda-confirms-a-pdufa-goal-date-of-august-30-2026-for-the-sbla-submission-of-ropeginterferon-alfa-2b-njft-in-essential-thrombocythemia-et/",
"snippet": "FDA Confirms a PDUFA Goal Date of August 30, 2026 for the sBLA Submission of Ropeginterferon Alfa-2b-njft in Essential Thrombocythemia (ET). · Jan 13, 2026",
"title": "FDA Confirms a PDUFA Goal Date of August 30, 2026 ..."
},
{
"link": "https://us.pharmaessentia.com/fda-approves-pharmaessentias-besremi-ropeginterferon-alfa-2b-njft-for-adults-with-essential-thrombocythemia-a-rare-blood-cancer/",
"snippet": "BESREMi has been approved for adults with ET, regardless of genotype or disease status BURLINGTON, Mass, August 31, 2026 · Aug 31, 2026",
"title": "FDA Approves PharmaEssentia's BESREMi ..."
},
{
"link": "https://www.onclive.com/view/fda-approves-ropeginterferon-alfa-2b-for-essential-thrombocythemia",
"snippet": "FDA Approves PharmaEssentia's Besremi (ropeginterferon alfa-2b-njft) for adults with essential thrombocythemia, a rare blood cancer. · Aug 31, 2026",
"title": "FDA Approves Ropeginterferon Alfa-2b for Essential ..."
},
{
"link": "https://hq.pharmaessentia.com/en/news_latestdetail/PharmaEssentia-to-Present-New-Clinical-Data-Supporting-the-Use-of-Ropeginterferon-Alfa-2b-in-Essential-Thrombocythemia-at-ASCO-and-EHA-2026",
"snippet": "Ropeginterferon alfa-2b-njft is currently FDA-approved and marketed as BESREMi® for the treatment of adults with polycythemia vera (PV). The use of ...",
"title": "Latest News - News - PharmaEssentia-Ropeginterferon ..."
},
{
"link": "https://x.com/oncodaily/status/2094459108439073166",
"snippet": "US_FDA approves @PharmaEssentia's BESREMi (ropeginterferon alfa-2b-njft) for adults with essential thrombocythemia ... 9:15 AM · Aug 31, 2026 ... · 1 week ago",
"title": "Post"
}
],
"success": true
},
"error": "",
"elapsed": 0.860606452
}{
"tool_name": "web_search",
"tool_input": {
"num": 5,
"q": "Joenja leniolisib Pharming children 4-11 APDS FDA approval September 2026"
},
"dispatch_id": "toolu_bdrk_012SxPnUu1BJYsw4VEP5c7sD",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "web_search"
}{
"tool_name": "web_search",
"dispatch_id": "toolu_bdrk_012SxPnUu1BJYsw4VEP5c7sD",
"status": "completed",
"result": {
"count": 5,
"query": "Joenja leniolisib Pharming children 4-11 APDS FDA approval September 2026",
"results": [
{
"link": "https://www.pharming.com/our-news/pharming-announces-u-s-fda-acceptance-of-snda-resubmission-for-joenja",
"snippet": "FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS Regulatory & approvals June 4, 2026 · Jun 4, 2026",
"title": "Pharming announces U.S. FDA acceptance of sNDA ..."
},
{
"link": "https://www.pharming.com/our-news/pharming-group-receives-complete-response-letter-us-fda-snda-joenja-leniolisib-children",
"snippet": "Joenja's U.S. FDA approval for the treatment of APDS in patients aged 12 years of age and older is unaffected by this regulatory action. Fabrice ... · Feb 1, 2026",
"title": "Pharming Group receives Complete Response Letter from ..."
},
{
"link": "https://uk.finance.yahoo.com/news/fda-approves-pharming-joenja-first-180000437.html",
"snippet": "FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) ages 4 to 11 ... · 5 hours ago",
"title": "FDA approves Pharming's Joenja® as first treatment for ..."
},
{
"link": "https://www.clinicaltrialvanguard.com/news/fda-accepts-pharmings-leniolisib-resubmission-for-children-4-11-with-apds/",
"snippet": "FDA accepts Pharming's leniolisib resubmission for children 4-11 with APDS, targeting October 2026 decision after resolving manufacturing ... · Jun 4, 2026",
"title": "FDA Accepts Pharming's Leniolisib Resubmission for ..."
},
{
"link": "https://www.stocktitan.net/sec-filings/PHAR/6-k-pharming-group-n-v-current-report-foreign-issuer-a2a1bff35a67.html",
"snippet": "FDA accepts Pharming's resubmitted sNDA for Joenja in children 4–11 with APDS and sets an October 24, 2026 PDUFA date, aiming to expand its ... · Jun 4, 2026",
"title": "Pharming FDA accepts Joenja pediatric APDS resubmission"
}
],
"success": true
},
"error": "",
"elapsed": 1.299257285
}{
"tool_name": "write_file",
"tool_input": {
"content": "# FDA human drug approvals, Aug 28 – Sep 11, 2026\nSource: fda.gov Notable Approvals, What's New Related to Drugs, Novel Drug Approvals 2026.\n\n## Novel (new molecular entity / new biologic)\n| Drug | Indication | Sponsor | Date | Label limitations |\n|---|---|---|---|---|\n| Isembyld (apitegromab-mstn) | SMA, adults + peds >=2 yr already on an SMN2-targeted therapy | Scholar Rock | 9/11/2026 | Add-on only; efficacy shown in nonambulatory 2-12 yr; increased fracture risk incl. serious; fetal harm, may affect reproductive function |\n| Etcamah (camizestrant) | HR+/HER2- adv/metastatic breast cancer on ESR1 mutation detected during AI + CDK4/6i; used with abemaciclib, palbociclib or ribociclib | AstraZeneca | 9/4/2026 | Accelerated approval on PFS, confirmatory trial required; BOXED WARNING QTc prolongation/arrhythmia with QT drugs; bradycardia; embryo-fetal tox; requires Guardant360 CDx |\n| Zanvastro (zilganersen) | Alexander disease, pediatric + adult | Ionis | 9/3/2026 | Intrathecal q3mo by trained HCP; aseptic meningitis reported; <2 yr indication rests on PK modeling + 4 patients |\n| Mimrylo (rusfertide) | Erythrocytosis in adults with polycythemia vera | Takeda | 8/28/2026 | Studied in pts needing frequent phlebotomy despite standard care; injection site reactions, anemia |\n\n## Label expansions in window\n- Hyrnuo (sevabertinib), Bayer, 9/9/2026: accelerated approval, 1L HER2 (ERBB2) TKD-mutated non-squamous NSCLC. FDA-authorized test required; warnings diarrhea, hepatotoxicity, ILD/pneumonitis, LV dysfunction, ocular tox, pancreatic enzyme elevation, embryo-fetal tox.\n- Joenja (leniolisib), Pharming, 9/11/2026: APDS in children 4-11 weighing >=27 kg, weight-based dose. Not for moderate-to-severe hepatic impairment.\n- Besremi (ropeginterferon alfa-2b-njft), PharmaEssentia, 8/31/2026: adults with essential thrombocythemia.\n- Stelara (ustekinumab), 8/28/2026: pediatric ulcerative colitis.\n\nJust outside window: Lisraya (brepocitinib) 8/27 dermatomyositis; Rasonque (daraxonrasib) 8/26 metastatic pancreatic cancer.\n",
"file_path": "/workspace/work/fda-approvals-aug28-sep11-2026.md"
},
"dispatch_id": "toolu_bdrk_01Kx4jawHqm99NU259rDHZru",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": "write_file"
}{
"tool_name": "write_file",
"dispatch_id": "toolu_bdrk_01Kx4jawHqm99NU259rDHZru",
"status": "completed",
"result": "Successfully wrote 2045 bytes to /workspace/work/fda-approvals-aug28-sep11-2026.md. The user cannot open workspace paths: if this file is for them, deliver it with upload_file rather than telling them the path.",
"error": "",
"elapsed": 0.064247707
}{
"tool_name": "send_message",
"tool_input": {
"final": true,
"in_response_to": "2d179218",
"message": "Four genuinely novel drugs were approved Aug 28 to Sep 11, 2026, per FDA's [Novel Drug Approvals for 2026](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026) and [Notable Approvals](https://www.fda.gov/drugs/news-events-human-drugs/notable-approvals-drugs).\n\n| Drug | Indication | Sponsor | Date | Key label limitations |\n|---|---|---|---|---|\n| [Isembyld (apitegromab-mstn)](https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-therapy-target-muscle-loss-spinal-muscular-atrophy) | Spinal muscular atrophy, adults and children 2+ already on an SMN2-targeted therapy | Scholar Rock | Sep 11 | Add-on only, not monotherapy. Increased risk of fractures, including serious ones. May cause fetal harm and may affect reproductive function. Efficacy was shown in nonambulatory patients aged 2 to 12. |\n| [Etcamah (camizestrant)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative) | HR-positive, HER2-negative advanced or metastatic breast cancer once an ESR1 mutation appears during AI + CDK4/6i therapy, given with abemaciclib, palbociclib or ribociclib | AstraZeneca | Sep 4 | Accelerated approval on PFS, continued approval needs a confirmatory trial. Boxed warning for QTc prolongation and arrhythmia with concomitant QT-prolonging drugs. Also bradycardia and embryo-fetal toxicity. Requires the Guardant360 CDx ctDNA test. |\n| [Zanvastro (zilganersen)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-alexander-disease) | Alexander disease, pediatric and adult, the first approved treatment | Ionis | Sep 3 | Intrathecal injection every 3 months by a trained professional. Aseptic meningitis has been reported. The under-2 indication rests on PK modeling plus safety in only 4 infants. |\n| [Mimrylo (rusfertide)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder) | Erythrocytosis in adults with polycythemia vera, first-in-class hepcidin mimetic | Takeda | Aug 28 | Studied only in patients still needing frequent phlebotomy despite standard care. Most common reactions were injection site reactions and anemia. |\n\nFour label expansions landed in the same window: [sevabertinib (Hyrnuo, Bayer, Sep 9)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-locally-advanced-or-metastatic-non-squamous-non-small) got accelerated approval in untreated HER2 TKD-mutated non-squamous NSCLC, with warnings for diarrhea, hepatotoxicity, ILD/pneumonitis, left ventricular dysfunction, ocular toxicity and pancreatic enzyme elevation. [Joenja (leniolisib, Pharming, Sep 11)](https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-children-aged-4-11-years-apds-rare-genetic-disorder-immune-system) now covers APDS in children 4 to 11 who weigh at least 27 kg, and is contraindicated in moderate-to-severe hepatic impairment. [Besremi (PharmaEssentia, Aug 31)](https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-essential-thrombocythemia) added adult essential thrombocythemia. [Stelara (Aug 28)](https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-stelara-pediatric-ulcerative-colitis) added pediatric ulcerative colitis.\n\nTwo novel approvals fell just outside 14 days: Lisraya (brepocitinib) for adult dermatomyositis on Aug 27, and Rasonque (daraxonrasib) for metastatic pancreatic cancer on Aug 26."
},
"dispatch_id": "toolu_bdrk_01C2KCPncMsiSypHp39xLLi1",
"parent_dispatch_id": "",
"handle": "",
"panel_kind": ""
}{
"tool_name": "send_message",
"dispatch_id": "toolu_bdrk_01C2KCPncMsiSypHp39xLLi1",
"status": "completed",
"result": "Delivered (confirmed) as 4 messages. Your draft was polished into texting register, so the wording differs from what you wrote; this is exactly what the user sees:\n1) Four novel drugs approved Aug 28 to Sep 11, 2026 per the FDA's approvals page.\n2) ### Novel drug approvals Aug 28–Sep 11 · FDA approvals\n\n| Drug | Indication | Sponsor | Date | Key label limitations |\n|---|---|---|---|---|\n| [Isembyld (apitegromab-mstn)](https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-therapy-target-muscle-loss-spinal-muscular-atrophy) | Spinal muscular atrophy, adults and children 2+ already on an SMN2-targeted therapy | Scholar Rock | Sep 11 | Add-on only, not monotherapy. Increased risk of fractures, including serious ones. May cause fetal harm and may affect reproductive function. Efficacy was shown in nonambulatory patients aged 2 to 12. |\n| [Etcamah (camizestrant)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative) | HR-positive, HER2-negative advanced or metastatic breast cancer once an ESR1 mutation appears during AI + CDK4/6i therapy, given with abemaciclib, palbociclib or ribociclib | AstraZeneca | Sep 4 | Accelerated approval on PFS, continued approval needs a confirmatory trial. Boxed warning for QTc prolongation and arrhythmia with concomitant QT-prolonging drugs. Also bradycardia and embryo-fetal toxicity. Requires the Guardant360 CDx ctDNA test. |\n| [Zanvastro (zilganersen)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-alexander-disease) | Alexander disease, pediatric and adult, the first approved treatment | Ionis | Sep 3 | Intrathecal injection every 3 months by a trained professional. Aseptic meningitis has been reported. The under-2 indication rests on PK modeling plus safety in only 4 infants. |\n| [Mimrylo (rusfertide)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder) | Erythrocytosis in adults with polycythemia vera, first-in-class hepcidin mimetic | Takeda | Aug 28 | Studied only in patients still needing frequent phlebotomy despite standard care. Most common reactions were injection site reactions and anemia. |\n3) https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026\nhttps://www.fda.gov/drugs/news-events-human-drugs/notable-approvals-drugs\n4) Four label expansions: sevabertinib for untreated HER2 TKD-mutated NSCLC, leniolisib for children with APDS, Besremi for essential thrombocythemia, and Stelara for pediatric ulcerative colitis.\nThese are your words now, and this is the whole reply: the delivery layer chose its density and shape by design. Never dispute, re-explain, or apologize for the phrasing, and never send a supplement to restore detail it left out. Only a final send settles its request. Never chase wording with another send. If a fact in it is wrong and would change what the user does, correct it when their next message arrives.\n\nNothing else is open: no request awaits a reply and no work is running. A response with no tool call ends the run.\nanswers: 2d179218-7f8a-48ed-b8f3-0c98830071e1",
"error": "",
"elapsed": 7.407151733
}| Drug | Indication | Sponsor | Date | Key label limitations |
|---|---|---|---|---|
| Isembyld (apitegromab-mstn) | Spinal muscular atrophy, adults and children 2+ already on an SMN2-targeted therapy | Scholar Rock | Sep 11 | Add-on only, not monotherapy. Increased risk of fractures, including serious ones. May cause fetal harm and may affect reproductive function. Efficacy was shown in nonambulatory patients aged 2 to 12. |
| Etcamah (camizestrant) | HR-positive, HER2-negative advanced or metastatic breast cancer once an ESR1 mutation appears during AI + CDK4/6i therapy, given with abemaciclib, palbociclib or ribociclib | AstraZeneca | Sep 4 | Accelerated approval on PFS, continued approval needs a confirmatory trial. Boxed warning for QTc prolongation and arrhythmia with concomitant QT-prolonging drugs. Also bradycardia and embryo-fetal toxicity. Requires the Guardant360 CDx ctDNA test. |
| Zanvastro (zilganersen) | Alexander disease, pediatric and adult, the first approved treatment | Ionis | Sep 3 | Intrathecal injection every 3 months by a trained professional. Aseptic meningitis has been reported. The under-2 indication rests on PK modeling plus safety in only 4 infants. |
| Mimrylo (rusfertide) | Erythrocytosis in adults with polycythemia vera, first-in-class hepcidin mimetic | Takeda | Aug 28 | Studied only in patients still needing frequent phlebotomy despite standard care. Most common reactions were injection site reactions and anemia. |
### Novel drug approvals Aug 28–Sep 11 · FDA approvals | Drug | Indication | Sponsor | Date | Key label limitations | |---|---|---|---|---| | [Isembyld (apitegromab-mstn)](https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-therapy-target-muscle-loss-spinal-muscular-atrophy) | Spinal muscular atrophy, adults and children 2+ already on an SMN2-targeted therapy | Scholar Rock | Sep 11 | Add-on only, not monotherapy. Increased risk of fractures, including serious ones. May cause fetal harm and may affect reproductive function. Efficacy was shown in nonambulatory patients aged 2 to 12. | | [Etcamah (camizestrant)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative) | HR-positive, HER2-negative advanced or metastatic breast cancer once an ESR1 mutation appears during AI + CDK4/6i therapy, given with abemaciclib, palbociclib or ribociclib | AstraZeneca | Sep 4 | Accelerated approval on PFS, continued approval needs a confirmatory trial. Boxed warning for QTc prolongation and arrhythmia with concomitant QT-prolonging drugs. Also bradycardia and embryo-fetal toxicity. Requires the Guardant360 CDx ctDNA test. | | [Zanvastro (zilganersen)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-alexander-disease) | Alexander disease, pediatric and adult, the first approved treatment | Ionis | Sep 3 | Intrathecal injection every 3 months by a trained professional. Aseptic meningitis has been reported. The under-2 indication rests on PK modeling plus safety in only 4 infants. | | [Mimrylo (rusfertide)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder) | Erythrocytosis in adults with polycythemia vera, first-in-class hepcidin mimetic | Takeda | Aug 28 | Studied only in patients still needing frequent phlebotomy despite standard care. Most common reactions were injection site reactions and anemia. |